



CURRICULUM VITAE

Summary

More than 30 years' experience as a cardiologist. Medical degree at the University of Buenos Aires, Argentina. Residency/Cardiology Fellowship at the Favaloro Foundation at Sanatorio Guemes in Buenos Aires. Cardiac cath/intervention at the Favaloro Foundation/Sanatorio Guemes. International Scholar in Artificial Organs at the Cleveland Clinic in 1990 and Duke Clinical Research Institute Research Fellow in Clinical Trials under Robert M. Califf mentorship 1992-1994. In that period helped to develop with a group of Duke expert, the latino version of the Duke Databank for Cardiovascular Diseases. This was successfully operated until 1998 at the Favaloro Institute in Buenos Aires and one of the first electronic medical record (EMR). The experience is in the "Archives of the Duke Databank History"

http://digitaldukemed.mc.duke.edu/databank/barbagelata_interview.html

Member of the Cardiology Division at the University of Texas Medical Branch since March 2005 with the rank of associate professor of medicine, as a CCU and cardiac cath lab attending (invasive cardiologist) in all type of cardiovascular diseases with stronger focus in Advanced Heart Failure /Cardiogenic Shock.

Director or Co-director of the Heart Failure, Assist Devices and Transplant Medicine 2005-2013 at same University. Helped to establish a advanced heart failure fellowship program. Advanced Heart Failure clinic and Devices in Heart Failure both percutaneous such as aquapheresis, 2.5 impella, Cardiac Power 3.5-4lt, and surgical such as being part of the approval team for destination therapy on HM II. UNOS Director of Heart Failure and Transplant Medicine (2011-2013). Has experience in more than 5000 procedures in the cath lab with more than 600 hundred biopsies and a number of percutaneous circulatory supports. In addition, extensive experience in critical cardiovascular care and emergencies.

Long time Member of Board of Directors in DUCCS (Duke University Cardiovascular Studies) and current Vice-President of a network of Duke trained physicians dedicated to research and education in cardiovascular medicine. Since 2015 his main practice located in Buenos Aires and along with DUCCS collaboration a physician network was created through a one-year master program at the local Catholic University. More than 400 physicians in Latin-America were educated using an online tool focused mainly in heart failure, cardiomyopathies, pulmonary hypertension and CAD with strong link for research, education and patient care

In the patient care arena, I have a significant pool of private practice patients with privileges in different institutions for patient care with experience in cardiac imaging (nuclear/echo) and invasive cardiac patients.

The research interest focus is in Acute MI and Heart Failure. Has published in all major cardiovascular journals and contributed in different aspect of cardiovascular diseases.

In Advanced heart failure, particularly the acute decompensated and End Stage Heart Failure, focusing on prognostic factors, percutaneous and surgical devices in heart failure and transplant. In acute MI has worked in several aspect of early identification of STEMI with different patterns such as the description of the Sgarbossa Criteria for MI in LBBB or the new descriptors in Q wave/non-Q wave in the reperfusion era and the use of telemedicine for timeliness reperfusion with particular interest in improving the cardiovascular health delivery. Has a recently published book as coeditor in early care of STEMI and in a DUCCS multicenter trial assessing the use of smartphone 12-lead ECG for STEMI triage

As fellow of the American Heart Association and member of the AHA International speaker bureau, has worked with the International Committee in numerous activities such as being liaison in the past between American Heart Association and Interamerican Society of Cardiology. In addition, was speaker at the Mexican ANCAM society and the Mexican Society of Cardiology and keynote speaker in joint AHA session at Queretaro congress in Mexico as AHA representative, World Congress of cardiology in Sydney, Spanish and Italian Society of Cardiology and in the Argentinean Society and Federation of Cardiology. Instrumental in the signature of AHA God Red for Women program with the Italian and the Argentinean Society of Cardiology.

Currently Professor of medicine, cardiology (adj) at Duke University School of Medicine and Vice President of DUCCS. Current Director of the Advanced Heart Failure Postgraduate program at the Catholic University in Buenos Aires and practicing physician in Buenos Aires.

NAME	ALEJANDRO (ALEX) BARBAGELATA, MD, FAHA, FSCAI, FICA
------	---

Current Activities

- Invasive Cardiologist, Heart Failure specialist in practice in Buenos Aires
- Adjunct Professor of Medicine at Duke University School of Medicine
- Board of Directors DUCCS (Duke University Cooperative Society
- Director Advanced Heart Failure postgraduate program at the Catholic University in Buenos Aires
- AHA International Speaker Bureau
- SCAI Interventional Heart Failure Committee

Past position (2005- 2013)

Associate Professor of Medicine University of Texas Medical Branch
CCU and Cardiac Cath Lab Attending Physician
Division of Cardiology/ Invasive Cardiologist.
Director Heart Failure, Assist Devices and Transplant Medicine University of Texas Medical Branch.

UNOS (United Network for Organs Sharing) Primary Physician at University of Texas Medical Branch

Director Advanced Heart Failure and Transplant Fellowship Program University of Texas Medical Branch.

EDUCATION

Medical School

- March 1976-Jul 1982 University of Buenos Aires School of Medicine
- Post Graduate Training
- Apr 1983 – Apr 1984 Internship. 'Fundación Favalaro/Sanatorio Güemes', Buenos Aires, Argentina
- May 1984-Apr 1988. Residency/Cardiology Fellowship. 'Fundación Favalaro/Sanatorio Güemes'. Buenos Aires, Argentina
- April-Dec 1982. Annual Program in Methodology and Application of Radioisotopes. National Commission of Atomic Energy, Buenos Aires, Argentina.
- Apr-Dec 1983 Advanced Course in Nuclear Medicine. Hospital de Clínicas, Buenos Aires, Argentina. Board Certified in Nuclear Medicine
- Apr-Oct 1986 Course in Biomedical Engineering, 'Fundación Favalaro, Buenos Aires, Argentina
- Apr 1987- Nov 1988 Bi-annual program for Cardiology certification, Argentine Society of Cardiology. Buenos Aires, Argentina
- Apr 1988-Dec 1989 Cardiovascular fellowship in diagnostic and interventional catheterization. Sanatorio Güemes - Fundación Favalaro, Buenos Aires, Argentina.
- 1988-1989 Internship Basic Research Department. Fundación Favalaro, Buenos Aires, Argentina
- Oct-Dec 1990 International Scholar. Circulatory Assistance and Artificial Heart. Cleveland Clinic Foundation, Cleveland, Ohio.
- Mar 1990- Feb 1992 Annual master's in research Methodology, 'Universidad de Belgrano', Buenos Aires, Argentina
- Jul-Nov 1992 Clinical Decision-Making Program (six months program). Clínica Suizo, Buenos Aires, Argentina
- 1992-1994 Cardiovascular Research Fellowship. Duke Clinical Research Institute, Durham, North Carolina.
- Jan Feb 1994 Intensive Program in Clinical Research. Duke University Medical Center. Biomedical Statistics and SAS, Clinical Epidemiology, Clinical Trials, Clinical Decision Making. Durham, North Carolina.
- 2009-2011 Scholar in Education program at the University of Texas Medical Branch (2 years program (2009-2011) Final Original Research presentation

PROFESSIONAL WORK EXPERIENCE

- May 1988-1992 Staff Member in CCU and Postoperative Cardiovascular Recovery Unit and Outpatient Cardiology Unit. Fundación Favalaro, Sanatorio Güemes - Buenos Aires, Argentina.
- 1992 –1994 Vice Chairman of the Clinical Research Division, Fundación Favalaro, Buenos Aires, Argentina.
- Jul 1992-Oct 1999 Faculty member in the cardiovascular unit, staff member in nuclear Cardiology, inpatient and outpatient Fundación Favalaro, Buenos Aires, Argentina.
- Mar 1996 –Sept 1998 Director of the Clinical research division and the Cardiovascular Databank. Fundación Favalaro, Buenos Aires, Argentina.
- Mar 2000-2005 Associate Director. Trials Argentina Group Organization, Buenos Aires, Argentina.

- Mar 2000-2005 Associate Physician. Invasive and Interventional Cardiology Service. Buenos Aires Italian Hospital. Buenos Aires-Argentina
- April 2005-present Staff Member Cardiology division. Invasive Cardiologist. Attending Cardiologist CCU, stepdown Unit
- 2005-Present Staff Member Cardiac Catheterization Laboratory University of Texas Medical Branch (Myocardial Biopsies Coronary, peripheral, carotid angiograms, Percutaneous Assist Devices, IABP, impella 2,5, Cardiac Power Abiomed 3.5-4, Vasodilator challenges)
- 2005 to Sept 2013. Advanced Heart Failure outpatient clinic, Texas city and League City
- 2006 to Sept 2013 Director Advanced Heart Failure and Transplant Fellowship Program.
- 2008 to Sept 2013. UTMB Associate Director of Heart Failure, Assist Devices and Transplant, University of Texas Medical Branch.
- 2011-2013 UNOS Primary Physician Heart Failure and Transplant Program
- 2011-2103 CMS VAD Cardiologist for Destination Therapy VAD Program
- 2013-Current Asst Professor Medicine/Cardiology. (Adj) Duke University School of Medicine
- 2013-Current DUCCS Board of Directors. Duke University Cooperative Society
- 2015-Current Director of the Heart Failure Postgraduate Program at Catholic University of Argentina
- Establishing Advanced Heart Failure program in Bs As Argentina
- Invasive Cardiologist in practice (privileges in Inst del Dco, Inst Fleni, Suizo Argentina) in Buenos Aires

TEACHING EXPERIENCE

- 1995 Teaching Professor in the Cardiology Superior Program 'Fundación Favaloro'. Buenos Aires, Argentina.
- 1996, 2000 Teaching Professor in the Cardiology Superior Program. Entre Rios Society of Cardiology. Buenos Aires, Argentina
- 2002, 2003 Co-Director Clinical Research Course. 'Trials Argentina Group Organization' Duke Clinical Research Institute.
- 2003 Teaching professor in the Clinical Trials Course. Margulies Foundation. Buenos Aires University. School of Medicine.
- 2003 Teaching Professor in the Cardiology Superior Program. Argentine Society of Cardiology. Heart Failure Treatment, Buenos Aires, Argentina.
- 2004 Teaching Professor in the Cardiology Superior Program. Argentine Society of Cardiology Heart Failure. Buenos Aires, Argentina.
- 2004 Co-Director, Scientific Program, First Patagonic Cardiovascular Conference at the End of the World. Usuahia, Argentina, October 2004.
- 2005 to 2013 Teaching Attending Faculty in Cardiovascular Diseases, University of Texas Medical Branch for cardiology and heart failure fellows, internal medicine residents and interns, school of medicine students
- 2007 to 2013 Yearly Lecture Heart Failure and Treatment. School of Medicine second year students. University of Texas Medical Branch UTMB
- 2010-2020 Board of Directors member at DUCCS (Duke University Cardiovascular Society)
- 2006 to 2013 Director of Advance Heart Failure Fellowship Program at University of Texas Medical Branch UTMB

- 2016- up to date. Director Post Graduate Program in Advanced Heart Failure. Catholic University Argentina-DUCCS
- Co-director of the Annual Conference Heart Failure Management in the Polypharmacy and Device Era

AMERICAN HEART ASSOCIATION ACTIVITIES

2014 World Congress of Cardiology 2014, Prehospital care of Acute Myocardial Infarction. Sydney Australia
 2014 AHA ANCAM (Mexican Society) cooperation agreement participation and joint session
 2015 AHA-Interamerican Society of Cardiology liaison
 2016 AHA representative. Sociedad Mexicana de Cardiología, Queretaro Mexico.
 Julio 1-3, 2016.
 2017 AHA SMC (Mexican Society of Cardiology) cooperation agreement participation and joint session
 2018 AHA FAC (Argentinean Society of Cardiology) Cooperation agreement with GRFW license signed
 2018 AHA Spanish Society of Cardiology joint symposium. SEC-ACC-AHA
 2018 AHA representing at Indian Heart Failure Education Program (Chennai)
 2019 AHA AMNCO (Italian Society of Cardiology Cooperation agreement with GRFW license signed
 2019 Sesión Conjunta AHA FAC Enfermedad Cardiovascular en la Mujer
 May 2019 AHA AMNCO (Italian Society of Cardiology) joint symposium
 Nov 2019 20 years of the "Lancisi Heart Days" the "AHA-ANMCO Go Red For Women Symposium"
 21st - 23rd November 2019, Ancona, Italy
 2021 AHA Conference "Heart Failure in Women" at Cardioacademics Symposium. Mexico
 2021 AHA/SAC Joint Session at the Argentinean Society of Cardiology
 2022 AHA/SIAC Joint Session AHA/SIAC Miami
 2023 May 2023 AHA AMNCO (Italian Society of Cardiology) joint symposium
 2023 FAC - SEC -AHA Fibrilación auricular. Lo que el clínico debe saber
 2024 Sesión Conjunta AHA SMC Acapulco
 2025 Sesión Conjunta AHA FAC Mendoza
 2026 President Congress AMNCO Il Tuo Cuore Foundation. Rome Italy

JOURNAL REVIEWER

American Journal of Cardiology (in the past)
 American Heart Journal (in the past)
 Journal of Electrocardiology (since 2001). Editorial Board Member
 Reviewer Clinical Cardiology 2011
 Reviewer Postgraduate Medicine 2012
 Editorial Board Member Journal of Clinical Trials in Cardiology
 International Editor Journal of Latin American Heart Failure (Revista Insuficiencia Cardíaca (Since 2015) Editorial Board Member

1. Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute myocardial infarction. TAMI Study Group. Barbagelata A, Granger CB, Topol EJ, Worley SJ, Kereiakes DJ, George BS, Ohman EM, Leimberger JD, Mark DB, Califf RM. *Am J Cardiol*. 1995 Nov 15;76(14):1007-13. doi: 10.1016/s0002-9149(99)80285-9. PMID: 7484852
2. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-I (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. Sgarbossa EB, Pinski SL, Barbagelata A, Underwood DA, Gates KB, Topol EJ, Califf RM, Wagner GS. *N Engl J Med*. 1996 Feb 22;334(8):481-7. doi: 10.1056/NEJM199602223340801.
3. Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary Arteries. Betriu A, Califf RM, Bosch X, Guerci A, Stebbins AL, Barbagelata NA, Aylward PE, Vahanian A, Van de Werf F, Topol EJ. *J Am Coll Cardiol*. 1998 Jan;31(1):94-102. doi: 10.1016/s0735-1097(97)00428-2. PMID: 9426024
4. Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators.
5. Goodman SG, Langer A, Ross AM, Wildermann NM, Barbagelata A, Sgarbossa EB, Wagner GS, Granger CB, Califf RM, Topol EJ, Simoons ML, Armstrong PW. *Circulation*. 1998 Feb 10;97(5):444-50. doi: 10.1161/01.cir.97.5.444. PMID: 9490238
6. Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators. Barbagelata A, Califf RM, Sgarbossa EB, Goodman SG, Stebbins AL, Granger CB, Suarez LD, Borruel M, Gates K, Starr S, Wagner GS. *J Am Coll Cardiol*. 1997 Mar 15;29(4):770-7. doi: 10.1016/s0735-1097(96)00587-6. PMID: 9091523
7. TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis. Barbagelata NA, Granger CB, Oqueli E, Suárez LD, Borruel M, Topol EJ, Califf RM. *Am Heart J*. 1997 Mar;133(3):273-82. doi: 10.1016/s0002-8703(97)70220-5.
8. Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-type plasminogen activator] for Occluded Coronary Arteries. Sgarbossa EB, Pinski SL, Topol EJ, Califf RM, Barbagelata A, Goodman SG, Gates KB, Granger CB, Miller DP, Underwood DA, Wagner GS. *J Am Coll Cardiol*. 1998 Jan;31(1):105-10. doi: 10.1016/s0735-1097(97)00446-4. PMID: 9426026
9. The use of tomographic myocardial perfusion scanning to evaluate an electrocardiographic salvage estimation method in patients with acute myocardial infarction: an AMISTAD substudy. Acute Myocardial Infarction Study Adenosine. Barbagelata A, Di Carli MF, Sgarbossa EB, Califf RM, Clemmensen P, Criger DA, Gates KB, Gibbons RJ, Casabe H, Granger CB, Wagner GS, Mahaffey KW. *J Electrocardiol*. 1999;32 Suppl:111-3. doi: 10.1016/s0022-0736(99)90059-6. PMID: 10688313
10. The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. *Circulation* 1998; 97:2386-2395.
11. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction Study of ADenosine (AMISTAD) trial. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leeser MA, Browne KF, Eisenberg PR, Bolli R, Casas AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB. *J Am Coll Cardiol*. 1999 Nov 15;34(6):1711-20. doi: 10.1016/s0735-1097(99)00418-0.

12. ECG subanalyses in clinical trials: an investigator's perspective. Sgarbossa EB, Pinski SL, Barbagelata A, Goodman SG, Natale A, Gates KB, Wagner GS. *J Electrocardiol.* 1999;32 Suppl:114-21. doi: 10.1016/s0022-0736(99)90060-2. PMID: 10688314
13. Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial). Barbagelata A, Califf RM, Sgarbossa EB, Goodman SG, Knight D, Mark DB, Granger CB, Agranatti DA, Mautner B, Ohman EM, Suárez LD, Armstrong PW, Gates K, Wagner GS. *Am J Cardiol.* 2000 Jul 1;86(1):24-9. doi: 10.1016/s0002-9149(00)00823-7. PMID: 10867087
14. The correlation between presenting ST-segment depression and the final size of acute myocardial infarcts in patients with acute coronary syndromes. Asfour W, Bell S, Amkieh AM, Sgarbossa EB, Azzam RK, Clemmensen P, Cohen M, Eisenstein E, Goodman S, Grinfeld L, Holmvang L, Maynard C, Pahlm O, Selvester RH, Heden B, Shah A, Vaught C, Warner RA, Glancy DL, Wagner GS, Barbagelata A. *J Electrocardiol.* 2000;33 Suppl:61-3. doi: 10.1054/jelc.2000.20338. PMID: 11269243
15. Negative T waves shortly after ST-elevation acute myocardial infarction are a powerful marker for improved survival rate. Sgarbossa EB, Meyer PM, Pinski SL, Pavlovic-Surjancev B, Barbagelata A, Goodman SG, Lum AS, Underwood DA, Gates KB, Califf RM, Topol EJ, Wagner GS. *Am Heart J.* 2000 Sep;140(3):385-94. doi: 10.1067/mhj.2000.108835. PMID: 10966535
16. Comparison of primary coronary angioplasty versus thrombolysis in patients with ST-segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrollment electrocardiogram. Birnbaum Y, Goodman S, Barr A, Gates KB, Barbash GI, Battler A, Barbagelata A, Clemmensen P, Sgarbossa EB, Granger CB, Califf RM, Wagner GS. *Am J Cardiol.* 2001 Oct 15;88(8):842-7. doi: 10.1016/s0002-9149(01)01889-6. PMID: 11676944
17. Standards for the function of an academic 12-lead electrocardiographic core laboratory. Anderson ST, Pahlm O, Bacharova L, Barbagelata A, Chaitman BR, Clemmensen P, Goodman S, Hedén B, Klootwijk PJ, Lauer M, MacFarlane PW, Rautaharju P, Reddy S, Selvester RH, Sgarbossa EB, Underwood D, Warner RA, Wagner GS. *J Electrocardiol.* 2001 Jan;34(1):41-7. doi: 10.1054/jelc.2001.22028. PMID: 11239370
18. Grade III ischemia on presentation with acute myocardial infarction predicts rapid progression of necrosis and less myocardial salvage with thrombolysis. Birnbaum Y, Mahaffey KW, Criger DA, Gates KB, Barbash GI, Barbagelata A, Clemmensen P, Sgarbossa EB, Gibbons RJ, Rahman MA, Califf RM, Granger CB, Wagner GS; AMISTAD (Acute Myocardial Infarction Study of Adenosine) Investigators. *Cardiology.* 2002;97(3):166-74. doi: 10.1159/000063334. PMID: 12077570
19. Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Gheorghiade M, Gattis WA, Barbagelata A, Adams KF Jr, Elkayam U, Orlandi C, O'Connor CM; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure Investigators. *Am Heart J.* 2003 Feb;145(2 Suppl): S51-4. doi: 10.1067/mhj.2003.154.
20. Aborted infarction: the ultimate myocardial salvage. Dowdy L, Wagner GS, Birnbaum Y, Clemmensen P, Fu Y, Maynard C, Menown I, Sejersten M, Young D, Johanson P, Barbagelata A. *Am Heart J.* 2004 Mar;147(3):390-4. doi: 10.1016/j.ahj.2003.10.008.
21. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. *JAMA.* 2004 Apr 28;291(16):1963-71. doi: 10.1001/jama.291.16.1963. PMID: 15113814 Clinical Trial.
22. Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification. Perna ER, Macin SM, Canella JP, Augier N, Stival JL, Cialzeta JR, Pitzus AE, Garcia EH, Obregón R, Brizuela M, Barbagelata A. *Circulation.* 2004 Oct 19;110(16):2376-82. doi: 10.1161/01.CIR.0000145158.33801.F3. Epub 2004 Oct 11.

23. Prognostic value of predischARGE electrocardiographic measurement of infarct size after thrombolysis: insights from GUSTO I Economics and Quality of Life substudy. Barbagelata A, Califf RM, Sgarbossa EB, Knight D, Mark DB, Granger CB, Armstrong PW, Elizari M, Birnbaum Y, Grinfeld LR, Ohman EM, Wagner GS; GUSTO-1 Investigators. *Am Heart J*. 2004 Nov;148(5):795-802. doi: 10.1016/j.ahj.2004.04.046.
24. Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias. Shoaf SE, Elizari MV, Wang Z, Sekar K, Grinfeld LR, Barbagelata NA, Lerman J, Bramer SL, Trongé J, Orlandi C. *J Cardiovasc Pharmacol Ther*. 2005 Sep;10(3):165-71. doi: 10.1177/107424840501000304.
25. Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial. Barbagelata A, Di Carli MF, Califf RM, Garg J, Birnbaum Y, Grinfeld L, Gibbons RJ, Granger CB, Goodman SG, Wagner GS, Mahaffey KW; AMISTAD Investigators. *Am Heart J*. 2005 Oct;150(4):659-65. doi: 10.1016/j.ahj.2004.10.014.
26. Have we made progress in reducing time to reperfusion in the management of acute myocardial infarction? A last decade overview. The potential key role of wireless electrocardiographic transmission. Young D, Barbagelata A, Wagner G. *J Electrocardiol*. 2005 Oct;38(4 Suppl):94-5. doi: 10.1016/j.jelectrocard.2005.06.017. PMID: 16226081
27. Overview of acute decompensated heart failure in Argentina: lessons learned from 5 registries during the last decade. Perna ER, Barbagelata A, Grinfeld L, García Ben M, Címbaro Canella JP, Bayol PA, Sosa Liprandi A. *Am Heart J*. 2006 Jan;151(1):84-91. doi: 10.1016/j.ahj.2005.03.010.
28. Hypercalcemia-Induced ST Segment Elevation Mimicking Acute Myocardial Infarction. Shawn P E Nishi, MD; Nestor A Barbagelata, MD; Shaul Atar, MD; Yochai Birnbaum, MD; Enrique Tuero, MD. *J Electrocardiol*. 2006 Jul;39(3):298-300. Epub 2006 Feb 28.
29. Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure. Rangasetty UC, Gheorghiade M, Uretsky BF, Orlandi C, Barbagelata A. *Expert Opin Investig Drugs*. 2006 May;15(5):533-40. doi: 10.1517/13543784.15.5.533.
30. The prognostic value of the admission and predischARGE electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experience. Goodman SG, Fu Y, Langer A, Barr A, Tan M, Wagner GS, Barbagelata A, Sgarbossa EB, Birnbaum Y, Granger CB, Califf RM, Van de Werf F, Topol EJ, Armstrong PW; GUSTO-IIb Investigators. *Am Heart J*. 2006 Aug;152(2):277-84. doi: 10.1016/j.ahj.2005.12.022. PMID: 16875908
31. Denying reperfusion or falsely declaring emergency: the dilemma posed by ST-segment elevation. Barbagelata A, Ware DL. *J Electrocardiol*. 2006 Oct;39(4 Suppl):S73-4. doi: 10.1016/j.jelectrocard.2006.06.006. Epub 2006 Aug 17. PMID: 16916518
32. Electrocardiographic markers of reperfusion in ST-elevation myocardial infarction. Atar S, Barbagelata A, Birnbaum Y. *Cardiol Clin*. 2006 Aug;24(3):367-76, viii. doi: 10.1016/j.ccl.2006.04.007.
33. Electrocardiographic diagnosis of ST-elevation myocardial infarction. Atar S, Barbagelata A, Birnbaum Y. *Cardiol Clin*. 2006 Aug;24(3):343-65, vii. doi: 10.1016/j.ccl.2006.04.008.
34. Grade 3 ischemia on admission electrocardiogram and chest pain duration predict failure of ST-segment resolution after primary percutaneous coronary intervention for acute myocardial infarction. McGehee JT, Rangasetty UC, Atar S, Barbagelata NN, Uretsky BF, Birnbaum Y. *J Electrocardiol*. 2007 Jan;40(1):26-33. doi: 10.1016/j.jelectrocard.2006.06.001. Epub 2006 Oct 25. PMID: 17067628
35. Meta-analysis of published reports on the effect of statin treatment before percutaneous coronary intervention on periprocedural myonecrosis. Merla R, Reddy NK, Wang FW, Uretsky BF, Barbagelata A, Birnbaum Y. *Am J Cardiol*. 2007 Sep 1;100(5):770-6. doi: 10.1016/j.amjcard.2007.03.105. Epub 2007 Jun 27. PMID: 17719318
36. Time to reperfusion in acute myocardial infarction. It is time to reduce it! Barbagelata A, Perna ER, Clemmensen P, Uretsky BF, Canella JP, Califf RM, Granger CB, Adams GL, Merla R, Birnbaum Y. *J Electrocardiol*. 2007 Jul;40(3):257-64. doi: 10.1016/j.jelectrocard.2007.01.007.

37. Wireless ECG in Early Diagnosis and Triaging of ST-elevation Myocardial Infarction: The TIME Study. Ramanna Merla, MD¥; George L. Adams, MD‡; Yochai Birnbaum, MD*; Barry F Uretsky*, MD Galen S Wagner MD‡ Alejandro Barbagelata, MD* J Electrocardiology. Jan 40 (1 suppl): S39-41. 2007
38. Usefulness of ST depression with T-wave inversion in leads V (4) to V(6) for predicting one-year mortality in non-ST-elevation acute coronary syndrome (from the Electrocardiographic Analysis of the Global Use of Strategies to Open Occluded Coronary Arteries IIB Trial).
39. Atar S, Fu Y, Wagner GS, Rosanio S, Barbagelata A, Birnbaum Y. Am J Cardiol. 2007 Apr 1;99(7):934-8. doi: 10.1016/j.amjcard.2006.11.039. Epub 2007 Feb 15. PMID: 17398187
40. Effect of statin treatment before percutaneous coronary intervention on periprocedural myonecrosis: A meta-analysis of published studies. Merla R, Uretsky B, Fen Wei, Barbagelata A, Birnbaum Y. Am J. Cardiol 2007 Am J Cardiol. 2007 Sep 1;100(5):770-6
41. Why are Large Clinical research Databases Needed? Alejandro Barbagelata. Manuscript Published Online Computers in Cardiology October 2007
42. Non-Ischemic ST Segment Elevation: a Frequent Finding in General Hospital Population. Enrique Tuero, Yochai Birnbaum, Alejandro Barbagelata, Barry F Uretsky. ACC 2007. Abstract published online Computers in Cardiology. October 2007
43. Diastolic Dysfunction (DD) Is a Useful Marker to Risk Stratify Patients with Frequent COPD Exacerbations and Normal Left Ventricular Ejection Fraction (LVEF). Ghassan Abu Said, Gulshan Sharma, Enrique Tuero, Wissam Khalife, Oscar Paniagua, Alejandro Barbagelata
44. VOLUME 14, ISSUE 6, SUPPLEMENT, S86, AUGUST 2008.
45. DOI:<https://doi.org/10.1016/j.cardfail.2008.06.232>
46. Management of hypertension in chronic heart failure. Manickavasagam S, Merla R, Koerner MM, Fujise K, Kunapuli S, Rosanio S, Barbagelata A. Expert Rev Cardiovasc Ther. 2009 Apr;7(4):423-33. doi: 10.1586/erc.09.8.
47. Diastolic dysfunction and COPD exacerbation. Abusaid GH, Barbagelata A, Tuero E, Mahmood A, Sharma G. Postgrad Med. 2009 Jul;121(4):76-81. doi: 10.3810/pgm.2009.07.2033.
48. Overcoming barriers to developing seamless ST-segment elevation myocardial infarction care systems in the United States: recommendations from a comprehensive Prehospital 12-lead Electrocardiogram Working Group. Frendl DM, Palmeri ST, Clapp JR Jr, Hampton D, Sejersten M, Young D, Drew B, Farrell R, Innes J, Russell J, Rowlandson GI, Purim-Shem-Tov Y, Underhill BK, Zhou S, Wagner GS; Journal of Electrocardiology Prehospital 12-lead ECG Working Group. J Electrocardiol. 2009 Sep-Oct;42(5):426-31. Epub 2009 May 15.
49. Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem. Gopal M, Bhaskaran A, Khalife WI, Barbagelata A. Curr Cardiol Rev. 2009 May;5(2):149-54. doi: 10.2174/157340309788166705.
50. The new concept of interventional heart failure therapy--part 1: electrical therapy, treatment of CAD, fluid removal, and ventricular support. Thompson KA, Philip KJ, Barbagelata A, Schwarz ER. J Cardiovasc Pharmacol Ther. 2010 Jun;15(2):102-11. doi: 10.1177/1074248410366447.
51. Cardiac calcitonin gene-related peptide and left ventricular hypertrophy in the cardiac allograft. Huang MH, Lui CY, Abusaid GH, Poh KK, Barbagelata AN, Uretsky BF, Fujise K. J Heart Lung Transplant. 2010 Apr;29(4):487-8. doi: 10.1016/j.healun.2009.11.002. Epub 2009 Dec 22.
52. Hypothyroidism and renal function in patients with systolic heart failure. Merla R, Martinez JD, Martinez MA, Khalife W, Bionat S, Bionat J, Barbagelata A. Tex Heart Inst J. 2010;37(1):66-9.
53. From theory to practice: implementation of pre-hospital electrocardiogram transmission in ST-elevation myocardial infarction - a multicenter experience. Adams G, Abusaid G, Lee B, Maynard C, Campbell P, Wagner G, Barbagelata A. J Invasive Cardiol. 2010 Nov;22(11):520-5.

54. Calcitonin Gene-Related Peptide as a Potential Marker of Compensation in Patients with Acute Heart Failure Exacerbations. Adib Asrabadi, Alejandro Barbagelata, Ming-He Huang, Vishal Kapur. VOLUME 15, ISSUE 6, SUPPLEMENT, S37, AUGUST 2009 DOI:<https://doi.org/10.1016/j.cardfail.2009.06.330>
55. Prehospital wireless transmission of electrocardiograms showing presumed ST-elevation myocardial infarction to an on-call cardiologist's handheld device: can the reduction in time to reperfusion be maintained in a single community and achieved in larger and medically complex communities? George L. Adams, Ghassan H Abusaid, Benjamin A. Lee, Alejandro Barbagelata Journal of Electrocardiology, Volume 43, Issue 6, 2010, 645 ISSN 0022-0736, <https://doi.org/10.1016/j.jelectrocard.2010.10.015>.
56. Cardiac allograft vasculopathy: advances in diagnosis. Cai Q, Rangasetty UC, Barbagelata A, Fujise K, Koerner MM. *Cardiol Rev.* 2011 Jan-Feb;19(1):30-5. doi: 10.1097/CRD.0b013e3181fbde2f.
57. Transplantation of high panel-reactive antibody left ventricular assist device patients without crossmatch using on-bypass pheresis and alemtuzumab. Lick SD, Beckles DL, Piovesana G, Vaidya S, Indrikovs A, Barbagelata NA, Valentine V. *Ann Thorac Surg.* 2011 Oct;92(4):1428-34. doi: 10.1016/j.athoracsur.2011.04.064. Epub 2011 Aug 19. PMID: 21855854
58. Management of Stable Coronary Artery Disease: From COURAGE, FAMEII, to ISCHEMIA. Qiangjun Cai, Alejandro Barbagelata and Masood Ahmad. *J Clin Exp Cardiol* 2012, 3:5
59. Management of arrhythmias in heart failure. What a practicing physician should know in the current times. Ramineni R, Bheemarasetti MK, Baranchuk A, Mandalapu T, Mukku VK, Fujise K, Barbagelata A. *Cardiol J.* 2012;19(6):567-77. doi: 10.5603/cj.2012.0107.
60. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E; Heart Failure Clinical Research Network. *N Engl J Med.* 2012 Dec 13;367(24):2296-304. doi: 10.1056/NEJMoa1210357. Epub 2012 Nov 6.
61. International Congress on Electrocardiology 2011 in Kingston, Ontario, Canada. Baranchuk A, Barbagelata A. *J Electrocardiol.* 2012 May-Jun;45(3):193-4. doi: 10.1016/j.jelectrocard.2012.02.007. PMID: 22520958 No abstract available.
62. Use of impella ventricular assist device in patients with severe coronary artery disease presenting with cardiac arrest. Mukku VK, Cai Q, Gilani S, Fujise K, Barbagelata A. *Int J Angiol.* 2012 Sep;21(3):163-6. doi: 10.1055/s-0032-1324736
63. Very Late Development of Coronary Artery Aneurysm with Total Occlusion following Sirolimus-Eluting Stent Implantation. Mukku VK, Cai Q, Barbagelata A, Conti VR, Fujise K. *Int J Angiol.* 2012 Dec;21(4):229-32. doi: 10.1055/s-0032-1325653. PMID: 24293982
64. Percutaneous Hemodynamic Support (Impella) in Patients with Advanced Heart Failure and/or Cardiogenic Shock Not Eligible to PROTECT II Trial. Liu W, Mukku VK, Gilani S, Fujise K, Barbagelata A. *Int J Angiol.* 2013 Dec;22(4):207-12. doi: 10.1055/s-0033-1349167.
65. Periprocedural adverse events in cell therapy trials in myocardial infarction and cardiomyopathy: a systematic review. Alvarez PA, Schwarz ER, Ramineni R, Myatt P, Barbin C, Boissonnet C, Phan A, Maggioni A, Barbagelata A. *Clin Res Cardiol.* 2013 Jan;102(1):1-10. doi: 10.1007/s00392-012-0508-3. Epub 2012 Sep 28.
66. The left bundle-branch block puzzle in the 2013 ST-elevation myocardial infarction guideline: from falsely declaring emergency to denying reperfusion in a high-risk population. Are the Sgarbossa Criteria ready for prime time? Cai Q, Mehta N, Sgarbossa EB, Pinski SL, Wagner GS, Califf RM, Barbagelata A. *Am Heart J.* 2013 Sep;166(3):409-13. doi: 10.1016/j.ahj.2013.03.032. Epub 2013 Aug 6.

67. Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Solomon SD, Tendera M, van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB; RED-HF Committees Investigators. *Eur J Heart Fail.* 2013 Mar;15(3):334-41. doi: 10.1093/eurjhf/hfs204. Epub 2013 Jan 17.
68. Treatment of anemia with darbepoetin alfa in systolic heart failure. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees; RED-HF Investigators. *N. Engl J Med.* 2013 Mar 28;368(13):1210-9. doi: 10.1056/NEJMoa1214865. Epub 2013 Mar 10.
69. Sharif, Ramla, Parto, Parham, A, Gowda, Kumar, Arnav, Barbagelata, Alejandro et al
70. Electrocardiographic Predictors of False Activation of the Cardiac Catheterization Laboratory Catheterization and Cardiovascular Interventions. May 2013, 81(S1):173
71. Perspectiva de nueva aplicación de un viejo dispositivo de asistencia circulatoria en la insuficiencia cardiaca. August 2014 Alejandro Barbagelata. *Revista Argentina de Cardiología* 82(4):273-274.
72. An old assist device for a potential new indication in refractory heart failure. January 2014 Revista Argentina de Cardiología 82(4):257-258 DOI:10.7775/rac.v82.i4.4787
73. Availability of a baseline Electrocardiogram changes the application of the Sclarovsky-Birnbaum Myocardial Ischemia Grade. Carlsen EA, Bang LE, Køber L, Strauss DG, Amaral M, Barbagelata A, Warren S, Wagner GS. *J Electrocardiol.* 2014 Jul-Aug;47(4):571-6. doi: 10.1016/j.jelectrocard.2014.02.010. Epub 2014 Mar 2.
74. The Role of Echocardiography in Heart Failure, Part 1-Kamel Sadat, MD, Masood Ahmad, MD, Qiangjun Cai, MD, Mohamed Morsy, MD, Navin Nanda, MD, Alejandro Barbagelata, MD, Wissam Khalife, MD. *Consultant.* 2014;54(8):614-617
75. The Role of Echocardiography in Heart Failure, Part 2 09/04/14 -Kamel Sadat, MD, Masood Ahmad, MD, Qiangjun Cai, MD, Mohamed Morsy, MD, Navin Nanda, MD, Alejandro Barbagelata, MD, Wissam Khalife, MD *Consultant.* 2014; 54(9):693-698
76. Smartphone ECG for evaluation of STEMI: results of the ST LEUIS Pilot Study. Muhlestein JB, Le V, Albert D, Moreno FL, Anderson JL, Yanowitz F, Vranian RB, Barsness GW, Bethea CF, Severance HW, Ramo B, Pierce J, Barbagelata A, Muhlestein JB. *J Electrocardiol.* 2015 Mar-Apr;48(2):249-59. doi: 10.1016/j.jelectrocard.2014.11.005. Epub 2014 Dec 27.
77. New Impella Cardiac Power Device Used in Patient with Cardiogenic Shock due to Nonischemic Cardiomyopathy. Cena M, Karam F, Ramineni R, Khalife W, Barbagelata A. *Int J Angiol.* 2016 Dec;25(4):258-262. doi: 10.1055/s-0034-1384822. Epub 2014 Dec 2.
78. Unmet goals in the treatment of Acute Myocardial Infarction: Review. Farah A, Barbagelata A. *F1000Res.* 2017 Jul 27;6: F1000 Faculty Rev-1243. doi: 10.12688/f1000research.10553.1. eCollection 2017
79. Smartphone ECG for evaluation of ST-segment elevation myocardial infarction (STEMI): Design of the ST LEUIS International Multicenter Study. Barbagelata A, Bethea CF, Severance HW, Mentz RJ, Albert D, Barsness GW, Le VT, Anderson JL, Bunch TJ, Yanowitz F, Chisum B, Ronnow BS, Muhlestein JB. *J Electrocardiol.* 2018 Mar-Apr;51(2):260-264. doi: 10.1016/j.jelectrocard.2017.10.011. Epub 2017 Oct 19.
80. Feasibility of Using a Smartphone Mobile ECG System to Detect ST-Elevation Myocardial Infarction: Primary Results of the ST LEUIS Trial Muhlestein JB, ^{a,b}, Anderson JL MD^{a,b}, Bethea CF, Severance H, Mentz RJ MD^d, Gregory W. Barsness MD^f, Alejandro Barbagelata MD^h, David Albert MD^e, Viet T. Le PA-C^{a,j}, T. Jared Bunch MD ^{a,i}, Frank Yanowitz MD^{a,b}, Heidi T. May PhD^a, Benjamin Chisum BS^a, Brianna S. Ronnow MS^a, Joseph Brent Muhlestein MD^{a,b} for the Duke University Cooperative Cardiovascular Society (DUCCS) investigators. *Am Heart J.* 2020 Mar; 221:125-135. doi: 10.1016/j.ahj.2019.12.016. Epub 2019 Dec 27. PMID: 31986289

81. Smartphone 12-lead ECG-Exciting but must be handled with care. Muhlestein JB, Muhlestein JB, Anderson JL, Bethea CF, Severance HW, Mentz RJ, Barsness GW, Barbagelata A, Albert D, Le VT, Bunch TJ, Yanowitz F, May HT, Chisum B, Ronnow BS; Duke University Cooperative Cardiovascular Society (DUCCS) investigators. *Am Heart J.* 2020 Aug; 226:269. doi: 10.1016/j.ahj.2020.03.004. Epub 2020 Mar 8. PMID: 32811641
82. A CASE REPORT MAY SPEAK LOUDER THAN A THOUSAND WORDS: DIRECT COVID-19 EFFECTS AND INDIRECT EFFECTS OF ISOLATION. MYOCARDIAL INFARCTION DURING THE PANDEMIC Liliana Noemí Nicolosi,¹ Mauro Basconcel,¹ Alejandro Barbagelata, María del Carmen Rubio. *Revista Medicina,* 2020
83. Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol. Cohen JB, Hanff TC, Corrales-Medina V, William P, Renna N, Rosado-Santander NR, Rodriguez-Mori JE, Spaak J, Andrade-Villanueva J, Chang TI, Barbagelata A, Alfonso CE, Bernales-Salas E, Coacalla J, Castro-Callirgos CA, Tupayachi-Venero KE, Medina C, Valdivia R, Villavicencio M, Vasquez CR, Harhay MO, Chittams J, Sharkoski T, Byrd JB, Edmonston DL, Sweitzer N, Chirinos JA. *J Clin Hypertens* 2020 Oct;22(10):1780-1788. doi: 10.1111/jch.14011. Epub 2020 Sep 16. PMID: 32937008
84. Prevención del colapso del sistema de salud en pacientes cardiovasculares con COVID-19: El rol del cardiólogo en la reducción de la sobrecarga de las unidades de cuidados intensivos con el advenimiento del frío en America del Sur. • Reporte de la Federación Argentina de Cardiología (FAC). Barbagelata Alejandro, Perna Eduardo, Piskorz Daniel, Lorenzatti Daniel. *Revista argentina de cardiología.* 2020
85. Héroes, vectores o víctimas Los profesionales de la Salud requieren todos los recursos indispensables para luchar contra la pandemia de CoViD-19. Sergio V. Perrone , Alejandro Barbagelata , Fabián Diez , Jorge Franchella , Arnaldo Angelino. *INSUFICIENCIA CARDIACA Insuf Card* 2020;15(2):52-62
86. Cohen, Jordana B., Thomas C. Hanff, Preethi William, Nancy Sweitzer, Nelson R. Rosado-Santander, Carola Medina, Juan E. Rodriguez-Mori, et al. "Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial." *Lancet Respir Med* 9, no. 3 (March 2021): 275–84. [https://doi.org/10.1016/S2213-2600\(20\)30558-0](https://doi.org/10.1016/S2213-2600(20)30558-0).
87. Alejandro Barbagelata, Juliana Giorgi, Michael M. Koerner, David A. Baran Multiorgan failure during COVID-19 pandemic in cardiovascular patients. Role of advanced cardiac and pulmonary support *Revista Argentina de Cardioangiología Intervencionista* 2020;11(2):58-64. <https://doi.org/10.30567/RACI/202002/0058-0064>
88. Roberto Cristodulo Cortéz ¹, Daniela Ureña Cordero, Mariana Sánchez, Pamela Rioja, Wilfredo Vidal, Erick Zambrana, Nathalie Rojas, Omar Escobar, Javier Ibáñez, Carlos Vaca, Sergio Perrone, Alejandro Barbagelata. Primer registro de insuficiencia cardíaca en la caja nacional de salud. *Registro PRICNASA. / Rev Fed Arg Cardiol.* 2021; 50(3): 104-109
89. Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction. Ospina González OE, Llanos Mejía DC, Kaplinsky E, Barbagelata A, Perrone S. *Drugs in Context.* 2023 Jan 4; 12:2022-6-4. doi: 10.7573/dic.2022-6-4. eCollection 2023. PMID: 36660017
90. Emerging concepts in heart failure management and treatment: focus on tachycardia-induced cardiomyopathy. Báez Cabanillas MV, Colque R, Tibaldi MÁ, Kaplinsky E, Perrone S, Barbagelata A. *Drugs in Context.* 2023 Jan 4; 12:2022-8-4. doi: 10.7573/dic.2022-8-4. eCollection 2023. PMID: 36660016
91. Cristodulo R, Luoma-Overstreet G, Leite F, Vaca M, Navia M, Durán G, Molina F, Zonneveld B, Perrone SV, Barbagelata A, Kaplinsky E. Dengue Myocarditis: A Case Report and Major Review. *Glob Heart.* 2023 Aug 4;18(1):41. doi: 10.5334/gh.1254. PMID: 37547170; PMCID: PMC10402786.
92. Emerging concepts in heart failure management and treatment: focus on vericiguat.
93. Kaplinsky E, Perrone S, Barbagelata A. *Drugs Context.* 2023 Jan 4; 12:2022-5-5. doi: 10.7573/dic.2022-5-5. eCollection 2023. PMID: 36660012

94. Emerging concepts in heart failure management and treatment: circulatory support with extracorporeal membrane oxygenation (ECMO). Swedzky F, Barbagelata A, Perrone S, Kaplinsky E, Ducharme A. *Drugs Context*. 2023 Jan 4; 12:2022-7-7. doi: 10.7573/dic.2022-7-7. eCollection 2023. PMID: 36660011
95. Emerging concepts in heart failure management and treatment: focus on point-of-care ultrasound in cardiogenic shock. Mariela Ruben, Maria Sol Molinas, Hugo Paladini, Alejandro Barbagelata January 2023, *Drugs in Context* 12:1-13 DOI:10.7573/dic.2022-5-8
96. Giorgi J, Barbagelata A, Luoma-Overstreet G, Kaplinsky E, Jorge SDC, Scanavacca M, Scordamaglio PR, Mentz RJ. 3D Printing for Left Ventricular Assist Device Exchange: Insights from Real-World Experience. *JACC Case Rep*. 2024 Jan 24;29(5):102194. doi: 10.1016/j.jaccas.2023.102194. PMID: 38464795; PMCID: PMC10920099.
97. F. Leonel Benaim¹, Franco S. Grazziani¹, Cecilia Villa Etchegoyen¹, Marcelo Boscaro², Edgardo Kaplinski³, Alejandro Barbagelata¹ Correlation of hemodynamic variables measured by impedance cardiography and right heart catheterization in pulmonary hypertension: a prospective cohort study. *Revista Argentina de Cardioangiología Intervencionista* 2024;15(4):197-204. <https://doi.org/10.30567/RACI/202404/197-204>
98. Ho VQT, Tran NB, Nguyen N, Arrighini GS, Downes D, Dandamudi M, Ferrara VZ, Ho THQ, Walia H, Barbagelata A, Leucker TM, Giorgi J. PCSK9 targeting therapies for familial hypercholesterolemia: a meta-analysis of efficacy on lipid biomarkers and safety in adults and children across 23 RCTs. *Open Heart*. 2025 Aug 21;12(2):e003490. doi: 10.1136/openhrt-2025-003490. PMID: 40841123; PMCID: PMC12374655.
99. Giorgi J, Cristodulo R, Vaca C, Ureña D, Rejas I, Rojas J, Espinoza F, Kaplinsky E, Barbagelata A. Clinical and Epidemiological Profile of Heart Failure Patients with Chagas Disease: Insights From the SEPE-HF Registry. *Am J Cardiol*. 2025 Aug 18; S0002-9149(25)00486-2. doi: 10.1016/j.amjcard.2025.08.024. Epub ahead of print. PMID: 40835081.
100. Tripoli A, Samaniego MA, Gamarra-Valverde NN, Selvam SP, Kaplinsky E, Barbagelata A, Scandroglia AM, Giorgi J. Efficacy and safety of apixaban versus vitamin K antagonists in patients with heartmate 3 fully magnetically levitated left ventricular assist device: a comprehensive meta-analysis. *J Thromb Thrombolysis*. 2025 Jul 1. doi: 10.1007/s11239-025-03141-y. Epub ahead of print. PMID: 40593455.
101. Special Issue: New Insights into Heart Failure Management and Treatment. *Medicina* 2025

ABSTRACT PRESENTATION

1. Barbagelata A, Sgarbossa E, Califf R, Woodlief L, Granger GS, Gates K, Starr S, Wagner GS. Non-Q wave myocardial infarction after thrombolytic therapy. One year prognosis after hospital discharge. A GUSTO 1 Substudy. *Circulation* 1994;90: I-664
2. Sgarbossa E, Barbagelata A, Califf R, Topol E, Wagner G, Pinski S. Diagnosis of acute myocardial infarction in the presence of left bundle branch block. A GUSTO 1 Substudy. Presented at the Orgain Symposium. Duke University Medical Center. 1994.
3. Sgarbossa EB, Pinski SL, Barbagelata NA, Underwood DA, Yamanouchi Y, Gates KB, Wagner G for the GUSTO investigator. Electrocardiographic diagnosis of impending acute myocardial infarction in the presence of left bundle branch block. Observation from GUSTO. *Circulation* 1994; 90: I-444.
4. Barbagelata NA, Pieper K, Califf RB. TIMI 3 Flow and reocclusion rates following thrombolysis in acute myocardial infarction. Results of an angiographics pooled analysis. *Circulation* 1994;90:I-220.
5. Sgarbossa EB, Pinski SL, Gates KB, Robinson K, Stein S, Woodlief LH, Barbagelata A, Wagner GS, Topol EJ and the GUSTO investigator. Outcome of patients with acute myocardial infarction and bundle branch block in the thrombolytic era: Observations from GUSTO. *J AM Coll Cardiol* 1995; 25:59 A
6. Barbagelata A, Bozovich G, Califf RM, Stebbins A, Granger CB, Gurfinkel E, Mautner B, Wagner GS for the GUSTO investigator. Non-Q wave myocardial infarction following thrombolytic therapy in GUSTO 1 patients. Comparison with different thrombolytic strategies. Presented at the International Cardiovascular Conference at Beaver Creek, Colorado 1995.
7. Goodman S, Langer A, Wildermann N, Barbagelata A, Sgarbossa EB, Wagner GS, Granger CB, Califf RM, Ross AM, Armstrong PW for the GUSTO Investigators Impact of thrombolysis on development of non-Q wave MI: an Angiographic Insights. Presented at the Canadian Cardiovascular Society Meeting, 1996.
8. Goodman SG, Langer A, Wildermann N, Barbagelata A, for the GUSTO-I Angiographic Investigators. Non-Q vs. Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the GUSTO-I angiographic substudy. *Circulation* 1995;92(Suppl I): I-530. Barbagelata A, Sgarbossa EB, Califf RM, Wagner GS, Granger CB, Knight D, Mark D, Agranatti D, Mautner B. Mortality, morbidity, resource use and quality of life following Q Vs non-Q-wave infarction and thrombolytic therapy: GUSTO substudy. *J Am Coll Cardiol* 1997;29: 490 A.
9. Gabe DE, Barbagelata A, Diez M, Casabe H, Suarez L, Mautner B. Importancia de la identificación de los pacientes con riesgo de eventos neurológicos posterior de cirugía de revascularización miocárdica. Interamerican Congress of Cardiology. Puerto Rico, 1997
10. Mahaffey KW, Puma JA, Barbagelata A, Casas C, Lambe L, Orlandi C, Califf RM, Granger CB. Does Adenosine in conjunction with thrombolysis reduce infarct size? Results from the controlled, randomized AMISTAD trial. *Circulation* 1997;96 (Suppl I):I 206
11. Casabe JH, Barbagelata NA, Oxilia A, Ferroni F, Miranda A, Garcia MB, Suarez LD, Gabe EG. Diabetes mellitus and coronary artery bypass surgery (CABG). Its importance in the 90's. *J Am Coll Cardiol* 1998;31: 315 C, 2585. Presented at the XIII World Congress of Cardiology 1998.
12. Gabe ED, Barbagelata NA, Merbilhaa R, Miranda A, Marta GM; Garcia B, Suarez LD, Casabe JH. Atrial fibrillation (AF) after coronary artery bypass surgery (CABG). Incidence, importance and cost. *J Am Coll Cardiol* 1998;31: 315 C. Presented at the XIII World Congress of Cardiology 1998.

13. Miranda A, Horacio C, Eduardo G, Barbagelata A, Merbilhaa R, Marta GB, Branco M, Luis S. CABG In patients with previous renal failure. Evolution and prognosis. J Am Coll Cardiol 1998; 31:314 C. Presented at the XIII World Congress of Cardiology 1998.
14. Barbagelata A, Sgarbossa EB, Califf RM, Wagner GS, Granger CB, Knight D, Suarez LD, Mark D. Prognosis and quality of life by electrocardiographic measures of infarct size after thrombolysis. A GUSTO-I substudy.. J Am Coll Cardiol 1998; 31:315 C. Presented at the XIII World Congress of Cardiology 1998.
15. Barbagelata A, Casabe H, Gabe E, Suarez LD. Coronary artery disease in the young (CABG). The role of smoking. J Am Coll Cardiol 1998; 31: 315 C. Presented at the XIII World Congress of Cardiology 1998.
16. Natale AA, Thompson TD, Sgarbossa EB, Wagner GS, **Barbagelata A**, Topol EJ, Califf RM. Different outcome of patients with sustained monomorphic ventricular tachycardia requiring cardioversion during acute myocardial infarction: Analysis in the GUSTO I Study. J Am Coll Cardiol 1998; 31:(Suppl A), 2, 96 A.
17. Casabe JH, Barbagelata NA, Caputo SA, Lódolo M, Garcia Ben M, Di Chiazza R, Gabe ED, Weinschelbaum E, Caramutti V, Suarez LD. Is female sex an independent risk factor for early mortality in coronary artery bypass graft surgery (CABG)? Presented at the European Soc of Cardiol, Vienna, Austria. August 22, 1998.
18. Sgarbossa EB, Pinski SL, Pavlovic-Surjancev B, Barbagelata A, Goodman SG, Underwood DA, Allen JE, Palvas B, Lum A, Starr S, Paredes A, Wagner GS. A new hierarchy for ECG stratification of acute myocardial infarction based in T wave polarity. A GUSTO I substudy. Circulation 1998;98 (supp I): I-555.
19. Di Carli MF, Barbagelata A, Mahaffey K, Casas C, Gibbons RJ, Califf RM, Granger CB, for the AMISTAD investigators. Does preinfarction angina reduce infarct size? An ancillary study from the control, randomize AMISTAD Trial. Circulation 1998;98: (supp I) I-630.
20. Gabe E, Kelzi T, Barbagelata A, Weinschelbaum E, Caramutti V, Rafaelli H. Risk stratification in coronary surgery. Eur Heart J 1998;19 (Suppl.):413
21. Casabe JH, Barbagelata NA, Caputo SA, Lodolo M, Garcia Benn M, Di Chaizza R, Gabe ED. Is female gender an independent risk factor for early mortality in coronary artery bypass surgery? Eur Heart J 1998; 19 (Suppl): 413
22. Barbagelata A, Di Carli M, Mahaffey KW, Califf RM, Suarez LD, Clemmensen P, Sgarbossa EB, Criger D, Gates K, Gibbons R, Casabe H, Granger CB, Wagner GS, for the AMISTAD Investigators. The comparison of an electrocardiographic salvage index with spect sestamibi scintigraphy in patients with acute myocardial infarction: An AMISTAD substudy. 'International Society for Computerized Electrocardiology' (ISCE) Nara, Japan. April 27, 1999.
23. Sgarbossa E, Barbagelata A, Goodman SG, Natale A, Gates KB, Wagner GS. ECG substudies from clinical trials: An investigators' perspective. 'International Society for Computerized Electrocardiology' (ISCE). Nara, Japan. April 27, 1999.
24. Asfour W, Benvd SB, Sgarbossa EB, Birnbaum Y, Clemmensen P, Eisenstein E, Goodman S, Holmvang L, Maynard C, Pahlm O, Selvester R, Grinfeld L, Shah A, Vaught C, Warner R, Wagner S, Barbagelata A. The correlation between presenting ST segment depression and the final size of acute myocardial infarcts in patients with acute coronary syndromes. 'International Society for Computerized Electrocardiology' (ISCE). Yosemite; California, April 30, 2000.
25. Birnbaum Y, Criger DA, Gates KB, Barbagelata A, Clemmensen P, Sgarbossa EB, Gibbons RJ, Wagner GW. Grade 3 ischemia on presentation in acute myocardial infarction predicts rapid progression of necrosis and less myocardial salvage with thrombolytic therapy. J Am Coll Cardiol 2001;37 (Suppl A):115 A.

26. Barbagelata A, Califf R, Sgarbossa E, Topol E, Wagner G, Pinski S, Granger C, Woodlief L, Gates K. Does the absence of Q wave at discharge make a different population in patients with acute myocardial infarction with ST elevation at admission and thrombolytic therapy? A GUSTO substudy. Orgain Symposium. Duke University Medical Center. 1994.
27. Liprandi MS, Liprandi AS, Barbagelata A, Garcia Benn M, Latorraga C, Orlandi C, Grinfeld L. Troponin T, but not high-sensitivity C-reactive protein, predicts outcomes in patients hospitalized with acute decompensated heart failure. *J Card Fail* 2003;9 (Suppl) : S90
28. Gheorghiade M, O'Connor C, Adams K, Gattis W, Barbagelata A, Elkayam U, Mc Grew F, Ghali J, Benza R, Klapholz M, Orlandi C for the ACTIV Trials Investigators. Acute and chronic therapeutic impact of a vasopressin 2 antagonist (Tolvaptan) in congestive heart failure (ACTIV in CHF): A placebo-controlled in patients hospitalized with heart failure. American Heart Association Scientific Sessions. Hot Line Session. Late Breaking Clinical Trial 2003.
29. Perna ER, Macin SM, Cimbaro Canella JP, Augier N, Pitzus AE, Riera JL, Stival, Cialzeta J, Garcia E, Barbagelata A, Jantus E. Ongoing myocardial damage in severe heart failure: prognostic usefulness of cardiac troponin T monitoring to identifying high risk patients *J Am Coll Cardiol* 2004; 43 (Supl A) : 226A.
30. O'Connor CM, Adams KF, Gattis WA, Barbagelata A, Elkayam U, McGrew F, Ghali J, Benza R, Klapholz M, Ouyang J, Orlandi C, Gheorghiade M, for the ACTIV in CHF Investigators. Predictors of mortality in patients hospitalized with worsening heart failure: Insights from the ACTIV in CHF Trial. *J Am Coll Cardiol* 2004; 43 (Supl A):181A.
31. Alejandro Barbagelata, MD, Peter Clemmensen, MD, Eduardo Perna, MD, Juan P Cimbaro Canella, MD, Liliana Grinfeld, MD, Yochai Birnbaum, MD, Galen S Wagner, MD. Have we made progress in reducing time to treatment in the management of acute myocardial infarction? A last decade overviews. The potential Key role of the ECG wireless transmission. ISCE 2005.
32. Eduardo Perna, MD, Alejandro Barbagelata, MD, Liliana Grinfeld, MD, Alvaro Sosa Liprandi, MD. Overview of acute decompensated heart failure in Argentina: Lessons learned from five registries during the last decade. *Journal of Cardiac Failure* 2005;11(6 Suppl), S186.
33. Sosa Liprandi MI, Sosa Liprandi A, Barbagelata, A, Pellegrini C, Lillan D, Garcia Benn M, Lopez M, Grinfeld L. Prognostic value of admission troponin T in patients with acute decompensated heart failure. *Rev Argent Cardiol* 2005;71 (Supl 3) :157
34. Barbagelata A, Covelli G, Fuselli H y col: Multiple Risk Factor Intervention Program HCNA. The First Argentina Multicenter Secondary Prevention Program in Cardiology. Risk factors analysis at baseline. V Congreso Mundial de Rehabilitación y Prevención Secundaria. Manila, Filipinas, febrero de 2000.
35. Cabo Fustaret M, Barbagelata A, Ballerio F, y col: Multiple Risk Factor Intervention Program HCNA. The First Argentine Multicenter Secondary Prevention Program in Cardiology. Six and twelve month follow-up. V Congreso Mundial de Rehabilitación y Prevención Secundaria. Manila, Filipinas, febrero de 2000.
36. Fuselli J, Covelli G, Cabo Fustaret M y col: Multiple Risk Factor Intervention Program HCNA. The First Argentine Multicenter Secondary Prevention Program in Cardiology. One year evolution of lipid profile and BMI. V Congreso Mundial de Rehabilitación y Prevención Secundaria. Manila, Filipinas, febrero de 2000.
37. Foyé R, Barbagelata A, Fuselli J y col: characteristics of the population entering a secondary prevention program. The HCNA. The First Argentine Multicenter Secondary Prevention Program in Cardiology. V Congreso Mundial de Rehabilitación y Prevención Secundaria. Manila, Filipinas, febrero de 2000.

38. Denying reperfusion or falsely declaring emergency: The dilemma posed by ST-segment elevation. Alejandro Barbagelata, MD, David Ware, MD. ISCE meeting Niagara Falls, Canada. April 2006
39. Martinez, J.D., Bionat, S.T., Merla, R., Saurabh, R., Bionat, J.S., Wang, F., Maity, S., Birnbaum, Y., Barbagelata, A. Renal function and thyroid status in heart failure. The 11th Annual Scientific meeting of the Heart Failure Society. *Journal of Cardiac Failure* 13 (Suppl 2): S95; 2007.
40. Non-Ischemic ST Segment Elevation: a Frequent Finding in General Hospital Population. Enrique Tuero, Yochai Birnbaum, Alejandro Barbagelata, Barry F Uretsky. Computers in Cardiology September 2007
41. Kapur V, Lui CY, Huang MH, Lakshman KM, Asrabadi A, Maity S, Barbagelata A. Calcitonin gene-related peptide as a neurohormonal marker in patients with Decompensated Heart Failure. *Circulation*, (suppl-II)116: 741, 2007.
42. Merla R, Reddy NK, Wang FW, Uretsky BF, Barbagelata A, Birnbaum Y. Effect of Statin Treatment before Percutaneous Coronary Intervention on periprocedural myonecrosis: A Meta-Analysis of published studies. Poster Presentation, National Student Research Forum, April 2007.
43. Vishal Kapur MD, Charles Y Lui MD, Ming H Huang MD, PhD, Kishore M Lakshman MD, MPH, Adib Asrabadi MD, Smita Maity MD, Alejandro Barbagelata MD. Calcitonin Gene-Related Peptide as a Neurohormonal Marker in Patients with Decompensated Heart Failure. American College of Physician. Texas Chapter 2008.
44. Abu Said G, Sharma G, Tuero E, Khalife W, Paniagua O, Barbagelata A. Diastolic Dysfunction (DD) Is a Useful Marker to Risk Stratify Patients with Frequent COPD Exacerbations and Normal Left Ventricular Ejection Fraction (LVEF)" 12th Annual Scientific meeting Heart Failure Society of America (September 21-24, 2008, Toronto, ON, Canada Abstract #452). *J Cardiac Failure* Vol 14, p S86
45. Calcitonin Gene-Related Peptide as a Potential Marker of Compensation in Patients with Acute Heart Failure Exacerbations Adib Asrabadi; Vishal Kapur; Alejandro Barbagelata; Ming-He Huang. *J Cardiac Failure* Vol. N Suppl 2009. P S37
46. Pre-hospital Wireless Transmission of Electrocardiograms Showing Presumed ST Elevation Myocardial Infarction to an On-call Cardiologist's Hand-held Device: Can the Reduction in Time to Reperfusion be Maintained in a Single Community and Achieved in Larger and Medically Complex Communities? International Society Computerized Electrocardiology New Mexico 2010 George L. Adams, MD1, Ghassan H. Abusaid, MD2, Benjamin A. Lee, BA1, Charles Maynard, PhD3, Paul T. Campbell, MD4, Galen S. Wagner, MD1, and Alejandro Barbagelata, MD. for the TIME-MC investigators.
47. Alemtuzumab, A promising Tool in the Rescue armamentarium for refractory allograft dysfunction with cardiogenic shock: Experience from a single institution. Killinsbury K, PA, Kollar A, Koerner M, Barbagelata A, Valentine V, Lick S. Presented at ISHLT 2010
48. Highly sensitized LVAD patients can be safely transplanted with non-crossmatched hearts using plasmapheresis and alemtuzumab: a contemporary case-control series. Lick S, Killinsbury K, Kollar A, Barbagelata A, Koerner MM, Valentine VG. Presented in a discussion section, ISHLT 2010.
49. Is Thoracic Impedance Cardiography ready to replace invasive techniques for measuring cardiac indices? Raminemi R, Rangasetty U, Fujise K, Barbagelata A, Merla R. *J Cardiac Failure* 2010. P S107-S108

50. Prediction of Findings for Patients Undergoing Coronary Angiogram (CA) to Rule Out Coronary Artery Disease (CAD) Venkata Kishore Mukku , M Bheemarasetti , K Fujise , A Barbagelata. Academy Master Teachers. Spring Symposium 2011
51. Systematic Analysis of adverse events in clinical stem cells trials in patients with acute myocardial infarction and cardiomyopathies. Ramineni R, Swarchzt E, Alvarez P, Barbagelata A. Presented at SCAI May 2011. Baltimore
52. Chronic intracardiac ischemia detection: 'A Jump into the Future' International Congress of Electrophysiology. Abu Said G, Barbagelata A. Kingston Canada. June 3-4 2011
53. Slow Continuous Ultrafiltration (SCUF) Improves Clinic Performance, Renal Function, and Serum Sodium levels in Advanced Decompensated Heart Failure Refractory to Conventional Diurectic Therapy. Xianfeng Wen MD PhD, Kershaw V. Patel BA, Alejandro Barbagelata MD. 54 Annual World Congress Internat College of Angiology 2012, Innsbruck, Austria.
54. Use of Impella Ventricular Assist Device in Patients with Severe Coronary Artery Disease Presenting with Cardiac Arrest. Venkatakishore Mukku, Qiangjun Cai, Syed Gilani, Ken Fujise, Alejandro Barbagelata American Heart Association 2011. 124: A50
55. Percutaneous Hemodynamic support (impella) in patients with advanced heart failure and/or cardiogenic shock not eligible to PROTECT II Trial. Wei Liu, Barbagelata A *Journal of Cardiac Failure* vol. 18 issue 8 August 2012. p. S101
56. Timmerman, KL, West, JN, Markofski, MM, Dhanani, S, Rasmussen, BB, Ckoki, KB, Barbagelata, NA, and Volpi, E. "Chronic Heart Failure is Associated with Elevated Skeletal Muscle Inflammation and Toll-Like Receptor 4 Signaling." April 2012
57. Sudhakar S, Barbagelata A, Sharma G. Validation of Readmission Risk Score and Readmission Rate in Heart Failure Patients at a Quaternary Hospital. American Heart Association 2013.

58. Clinical Predictors of False Activation of the Cardiac Catheterization Laboratory
Sharif, Ramla, Parekh Parto, Parham, A, Gowda, Kumar, Arnav, A, Hoang, Barbagelata, Alejandro. Catheterization and Cardiovascular Interventions 2013 81(S1):173

59. Electrocardiographic Predictors of False Activation of the Cardiac Catheterization Laboratory Sharif, Ramla, Parekh Parto, Parham, A, Gowda, Kumar, Arnav, A, Hoang, Barbagelata, Alejandro. Catheterization and Cardiovascular Interventions 2013, 81(S1):173

60. Joseph B. Muhlestein MD^{a,b}, Charles F. Bethea MD^c, Harry W. Severance MD^d, Alejandro Barbagelata MD^e, Robert J. Mentz MD^f, David Albert MD^g, Gregory W. Barsness MD^h, Viet T. Le PA-C^{aj}, T. Jared Bunch MD^{ai}, Frank Yanowitz MD^{a,b}, Benjamin Chisum BS^a, Heidi T. May^a, Brianna S. Ronnow MS^a, Joseph Boone Muhlestein MD^b, Jeffrey L. Anderson MD^a Determination of the Diagnostic Accuracy of a Mobile Smartphone ECG Device, when Compared to a Standard 12-Lead ECG Machine, for the Evaluation of ST-Segment Elevation Myocardial Infarction. Primary Results of the ST LEUIS International Multicenter Study. *Circulation*. 2018;138: A11623

61. Assessment of accuracy and reproducibility of coronary flow reserve measured by SPECT in patients with known or suspected coronary artery disease. Do Amaral Henrique De Souza A.1; Harms H. ; Campbell L. ; Bibbo C. ; Harrington M.1 ; Hainer J. ; Dorbala S. ; Blankstein R.1 ; Taqueti V. ; Kijewski M. ; Barbagelata A. ; Breault C. ; Park M.1 ; Di Carli M. *European Heart Journal Cardiovascular Imaging* · January 2020.
<https://www.researchgate.net/publication/338663648>

62. Randomized Comparison of Bare Metal Stents Plus Colchicine vs Drug Eluting Stents: Preliminary Analysis of the Orca Trial (Oral Colchicine in Argentina)
A.Matias Rodriguez-Granillo, Camila Correa-Sauduet, Juan Mieres, Valeria Curotto, Jose Milei, Sandra Sieszkowsky, Pablo Stutzbach, Carlos Fernandez-Pereira, Hernan Pavlovsky, Alejandro Barbagelata, Adnan Kastrati, Alfredo E Rodriguez from ORCA investigators. *Circulation Conference: American Heart Association's*; 146(Supplement 1), 2022.

63. Insuficiencia Cardíaca en Adultos Mayores: Análisis de una Población en Aumento. Rita Dasilva Salazar, Ana Quintero, Camila Alvarez, Rafael Porcile, Agustín Galindo, Andrea Castillo, Norberto Bornancini, Alejandro Barbagelata. Mexico City. Congreso SIAC Junio 2024

64. Samaniego, Giorgi, Barbagelata et al. Efficacy of Cardiac Myosin activators compared to placebo in patients with heart failure with reduced ejection fraction: A systematic review and metaanalysis of randomized controlled trials. ACC Latin American Mexico City setp 2025

65. Amiodarone Use in Left Ventricular Assist Devices. Patients Is Associated with Increased Risk of Mortality and Adverse Events: A Real-World Analysis from the TriNetX Platform. AHA Nov 9, 2025

ARGENTINEAN ABSTRACT PRESENTATION

1. Barbagelata A, Masoli O, Weinchelbaum E, Favaloro RG, Sanguinetti C. The value of the electrocardiogram for detecting myocardial viability in coronary patients with severe left ventricular dysfunction. Argentine Fed of Cardiol. 1990.

2. Barbagelata A, de la Fuente L, Weinchelbaum E, Wisner J, Méndez J, Favaloro RG. Emergent treatment of cardiogenic shock in acute myocardial infarction by CABG or PTCA. Re Arg de Cardiol. 1990.

3. Barbagelata A, de la Fuente L, Weinchelbaum E, Wisner J, Mendez J, Favaloro RG. Cardiogenic shock post myocardial infarction. Time dependence and anatomopathologic characteristics. Argentine Fed of Cardiol 1990.
4. Gomez I, Brandani L, Gurevich M, Barbagelata A, Favaloro RG. Informe sobre un caso de crioablación quirúrgica de haz anómalo complicado por una fibrosis pulmonar. Revi Arg Anest 1990.
5. Blanco G, Brandani L, Barbagelata A, Weinchelbaum E, Wisner J, Mendez J, Favaloro RG. Plasma cortisol after cardiopulmonary by-pass. Revi Arg Cardiol 1990.
6. Barbagelata A, Blanco G, Brandani L, Peltz G, Ruiz M, Mendez J, Weinchelbaum E, Favaloro RG. Mitral insufficiency post myocardial infarction in patients with myxomatosis valve. 2 Patients Case Report. Rev Argent Cardiol 1990; 58 (Suppl II) : 181
7. Barbagelata A, Brandani L, Blanco G, Peltz G, Ruiz M, Mendez J, Pesce R, Valero E, Weinchelbaum E, Favaloro RG. Predictive value of the complex ventricular arrhythmia after early surgery of reentry ventricular tachycardia. Rev Argent Cardiol 1990; 58 (Suppl II) : 133
8. Blanco G, Brandani L, Ruiz M, Peltz G, Barbagelata A, Mendez J, Favaloro RG. Hyperacute adult respiratory distress? Rev Argent Cardiol 1990; (Suppl II): 184
9. Brandani L, Quadrelli S, Peltz G, Ruiz M, Blanco G, Barbagelata A, Mendez J, Favaloro RG. Predictive value of the A/a gradient immediately after cardiac surgery with cardiocirculatory bypass Rev Argent Cardiol 1990; 58 (Suppl II) : 76
10. Barbagelata A, Bruno C, Vijnovich A, Blanco G, Brandani L, Peltz G, Ruiz M, Mendez J, Favaloro RG. Etiology in aortic valvular disease and aortic insufficiency in patients undergoing to aortic valvular replacement. Rev Argent Cardiol 1990; 58 (Suppl II)
11. Weinchelbaum E, Barbagelata A, Zaidman C, Figal J, Brandani L, Blanco G, Peltz G, Ruiz M, Méndez J, Favaloro RG. Comparison between aortic valvular repairment versus aortic valve replacement in patients with severe aortic stenosis older than 65 years old. Rev Argent Cardiol 1990; 58 (Suppl II) :130
12. Barbagelata A, Mendez J, Perrone SV, Gonzalez C, Wisner J, Tronge J, Weinchelbaum E, De la Fuente L, Favaloro RG. Early treatment with PTCA or CABG of cardiogenic shock after acute myocardial infarction. Rev Argent Cardiol. 1991; 59: 286
13. Barbagelata A, Bruno C, Vijnovich A, Blanco G, Brandani G, Peltz J, Ruiz M, Mendez C, Favaloro RG. Etiology in valvular aortic stenosis in patients undergoing aortic valvular replacement. Rev Argent Cardiol 1991; 58 (Suppl II) 36
14. Barbagelata A, Weinchelbaum E, Wisner J, Mendez J, Favaloro RG. Coronary by-pass surgery in coronary patients with severe left ventricular function. Rev Argent Cardiol 1991; 59 : 323

15. Barbagelata A, Califf RM, Bozovich G, Granger CB, Suarez L. Recurrent ischemia and reinfarction after thrombolysis. *Arg Fed Cardiol* 1995.
16. Eduardo G, García Benn M, Mas P, Barbagelata A, Varela E, Weinschelbaum E, Suárez L. Early risk stratification after CABG. *Rev Argent Cardiol* 1995; 63 (Suppl I) : 66. Presented at Favaloro Foundation, Buenos Aires.
17. Eduardo G, Barbagelata A, Swieszkowski S, Suárez L, Favaloro RG. Relationship between risk stratification and in-hospital stay in coronary patients undergoing to coronary by-pass graft surgery. Buenos Aires. *Rev Argent Cardiol* 1995; 63 (Suppl IV) : 67. Presented at Favaloro Foundation.
18. Barbagelata A, Oquelli E, Califf R, Sgarbossa E, Stebbins A, Goodman S, Granger C, Wagner G, Mautner B. Conversion rate to non-Q wave MI with different thrombolytic strategies. *Rev Arg Cardiol* 1996; 64 :135
19. Diez M, Gabe E, Barbagelata A, Mautner B, Suarez L, Casabé JH. Neurological complications after CABG. Incidence, prognostic and risk factors. *Rev Argent Cardiol* 1997; 65 (Suppl IV) : 43. Presented at Favaloro Foundation, Buenos Aires, Argentina.
20. Cendoya O, Oqueli E, Barbagelata A, Martinez J, Levi R, Agranatti D, Chwojnick A, Mele A, Marrero G, Mautner B. Relationship between peak CK and myocardial salvage in acute myocardial infarction treated with thrombolysis. *Rev Argent Cardiol* 1997; 65 (Suppl IV) : 125
21. Merbilha R, Gabe E, Barbagelata A, Miranda A, Casabe H. Importance of Renal Failure after Coronary Artery Bypass Graft. *Rev Argent Cardiol* 1997; 65 (Suppl IV): 109. Presented at Favaloro Foundation. Buenos Aires.
22. Martínez J, Oqueli E, Panno M, Fortunato M, Nusdeo S, Barbagelata A, Agranatti D, Chwojnik A, Cendoya O, Mautner B. Electrocardiographic versus SPECT SESTAMIBI estimation of final infarct size before discharge in patients with acute myocardial infarction. *Rev Argent Cardiol* 1997; 65 (Suppl IV): P5. Presented at Favaloro Foundation, Buenos Aires.
23. Dres Chwojnik A, Marrero G, Mele A, Cendoya O, Barbagelata A, Oqueli E, Mautner B, Malagraba G, Rossi N. Myocardial scintigraphic perfusion in patients with chest pain and acute impending myocardial infarction. *Rev Argent Cardiol* 1997; 65 (Suppl IV) : P7
24. Oqueli E, Fortunato M, Nusdeo S, Barbagelata A, Mo G, Agranatti D, Chwojnik A, Martinez J, Garcia Ben M, Mautner B., Suárez L. Comparison Between Electrocardiographic and SPECT Sestamibi acute infarct size estimation. *Rev Argent Cardiol* 1997; 65 (Suppl IV) :136. Presented at Favaloro Foundation. Buenos Aires.
25. Barbagelata A, Califf R, Mark D, Granger C. Prognosis and quality of life after thrombolysis by Electrocardiographic infarct size. GUSTO-I. *Rev Argent Cardiol* 1997; 65 (Suppl IV) : 14
26. Gabe E, Barbagelata A, Suárez L, Mautner B, Casabe H. Identification of patients in risk of neurological events after CABG. *Rev Argent Cardiol* 1997; 65 (Suppl IV) : 105
27. Barbagelata A, Caputo S, Casabe H, Garcia Ben M, Gabe E, Suarez LD. CABG and the young. The role of smoking. Presented at 7th Internal Medicine Congress. Hospital de clínicas. Buenos Aires 1998.

28. Caputo S, Pelagagge MJ, Barbagelata A, Casabe H, Oxilia A, Garcia Ben M, Gabe M, Suarez LD. Factores pronósticos en las mujeres sometidas a cirugía de revascularización miocárdica (CRM). Presented at 7th Internal Medicine Congress. Hospital de clínicas. Buenos Aires 1998.
29. Barbagelata A, Fortunato M, Pomés Iparaguirre H, Grancelli H, Molina Viamonte V, Mahaffey K W., Califf RM, Mautner B, Agranatti D, Granger CB. Adenosine and thrombolytic therapy in acute myocardial infarction. *Rev Argent Cardiol* 1998; 66 (Suppl IV) : 133
30. Barbagelata A, Casabe H, Racki M, Garcia Benn M, Suarez L, Gabe E. Diabetes in female but not in male sex predict coronary artery disease in patients referred to angiography. *Rev Argent Cardiol* 1998; 66 (Suppl IV) :145
31. Barbagelata A, Caputo S, Racki M, Suarez L, Gabe E, Casabe E. Female sex is the main diagnostic error of coronary artery disease. Favaloro Foundation, Buenos Aires. *Rev Argent Cardiol* 1998; 66(Suppl IV) : 149
32. Barbagelata A, Chwojnik A, Marrero G, Mele A, Cendoya O, Mahaffey KW, Granger CB, Califf R M, Mautner B, Gibbons R. Myocardial salvage index by TC ^{99m} sestamibi SPECT in patients with acute myocardial infarction treated with thrombolytic therapy and adenosine. An AMISTAD Substudy. *Rev Argent Cardiol* 1998;66 (Suppl IV) : 115
33. Hallon L, Diez M, Casabe H, Barbagelata A, Suarez L, Gabe E. Risk factors for neurological complication after CABG. Favaloro Foundation, Buenos Aires. *Rev Argent Cardiol* 1998;66 (Suppl IV) : 117
34. Pelagagge MJ, Caputo S, Casabe JH, Barbagelata A, Lódolo M, Gabe E, Di Chiazza R, Suarez L. Coronary artery disease in female sex. Incidence and clinical predictors. *Rev Argent Cardiol* 1998;66 (Suppl IV) : 100
35. Miranda A, Barbagelata A, Garcia BM, Suarez LD, Gabe E, Casabe H. Diabetes mellitus and CABG. *Rev Argent Cardiol* 1998;66 (Suppl IV) :148. Presented at Favaloro Foundation, Buenos Aires.
36. Lódolo M, Barbagelata A, Caputo S, Garcia Ben M, Di chiazza R, Gabe E, Weinschelbaum E, Caramutti V, Suarez L, Casabe J. Does the female sex constitute an independent risk factor for early mortality after CABG? *Rev Argent Cardiol* 1998;66 (Suppl IV) : 111
37. Pelagagge MJ, Caputo S, Casabe H, Barbagelata A, Lódolo M, Di Chiazza R, Gabe E, Suarez LD. Coronary artery disease in women. Incidence and clinical predictors. Presented at 7th Internal Medicine Congress. Hospital de clínicas. Buenos Aires, 1998.

CONFERENCES AND PARTICIPATION IN SCIENTIFIC MEETINGS

1. Fish Oil and Arteriosclerosis. 1992. Panelist. International Symposium of Ischemic Heart Disease. 25th Anniversary of Coronary Artery Bypass Graft. Favaloro Foundation, Buenos Aires Sheraton Hotel. June 19, 1992.
2. Treatment Selection in Chronic Coronary Heart Disease. The role of the Information Systems in Cardiology” 1994. Conference. International Symposium “Frontiers in Cardiology”. Austral University. July 25, 1994.
3. International Databanks 1994. Panel in Orgain symposium, Duke University Medical Center

4. Cardiovascular databanks in Cardiology Panel Symposium Medical Informatics (Córdoba 1994)
5. Strategies in the Acute Myocardial Infarction Treatment Panelist. Argentine Federation of Cardiology Congress Paraná, Entre Rios 1995
6. Unstable angina and non-Q wave MI. Panelist. Argentine Federation of Cardiology Congress Parana, Entre Rios, Argentina May 27, 1995
7. Hospital Information System in Cardiology First Conference on the Role of Medical Informatics in the Health Care System. Buenos Aires School of Medicine July 15, 1996. Buenos Aires, Argentina.
8. Controversie in Acute MI: Management. "Primary PTCA vs. Thrombolytics" "New Thrombolytic Agents in Acute Coronary Syndromes". Favaloro Foundation, Buenos Aires, Argentina. 1996.
9. Acute Coronary Syndromes. Panelist. First International Symposium . Instituto Cardiología de Rosario (ICR). Rosario, Argentina. May, 1996.
10. Intra-aortic balloon pump in Acute MI Panel. Symposium Unstable Angina and non-Q Wave MI. Panelist. XXIV Argentine Congress of Cardiology. Buenos Aires, Argentina. October 10th 1997.
11. Role of Communication Technology and Medical Informatics in the Health Care System. "Argentine Informatics and Communication Chamber". Videoconference with Duke University. VI International Congress in Telecommunications. Costa Salguero, Buenos Aires, Argentina. Nov, 1997.
12. "Unstable Angina". XXIV Argentine Congress of Cardiology. Moderator, poster session. Buenos Aires, Argentina. October 20, 1997.
13. Virtual Hospital, Panel Internet world 1998. April 1998.
14. Myocardial Protection in Acute MI Argentine Federation of Cardiology conference. Rosario, 1998.
15. Approach to the cardiovascular disease in the Diabetic Patient. XI Argentine Congress of Diabetes'. Córdoba, Argentina. October 11, 1998.
16. Role of Communication and Informatics in the Health Care System. 'Consejo de Ingenieros de la Capital Federal'. 1998
17. Myocardial Salvage in Acute Myocardial Infarction. Curso superior de médicos cardiólogos de la provincia de Buenos Aires, distrito IV'.
18. Clinical Cardiology. Argentine Symposium of Cardiology, Moderator, poster session. 1998.
19. Informatics and the Health Care System: Duke University Experience, Conference Fundación Favaloro. 'Institute for International Research S.A. Buenos Aires, Argentina. 1999
20. The Comparison of an Electrocardiographic Salvage Index with Spect Sestamibi Scintigraphy in Patients with Acute Myocardial Infarction: An AMISTAD substudy. The AMISTAD Salvage Index for the AMISTAD Investigators'.Conference. International Society of Computerized Electrocardiology. (ISCE). Nara, Japan, April 27, 1999.
21. Importance of Informatics in Medical Education. Internet world. 1999.
22. From Clinical Trials to clinical practice? Interamerican Symposium of Cardiology. 1999.
23. The Correlation Between Presenting ST Segment Depression and Final Infarct Size of Acute Myocardial Infarcts in Patients with Acute Coronary Syndromes. International Society of Computerized Electrocardiology. (ISCE). Yosemite, CA. April 29, 2000.

24. Hospitalization for Progression of Chronic Heart Failure. Co-Director. First International Symposium October First, 2001. XXVIII Argentine Congress of Cardiology, 2001.
25. Vasopressin Inhibition in Chronic Heart Failure. Symposium panelist. XXVIII Argentinean Congress of Cardiology 2001. October 2, 2001
26. New Directions in the Management of Chronic Heart Failure. The First Global Conference in Cardiovascular Clinical Trials: Previews and Reviews. Hong Kong, China. November 2001.
27. Hospitalization for Progression of Chronic Heart Failure. Second International Symposium XXIX Argentine Congress of Cardiology 2002
28. Renin-Angiotensin Inhibition for the Treatment of Chronic Heart Failure. IV Symposium of Heart Failure. Argentine Society of Cardiology. Buenos Aires, Argentina. September 2002.
29. Influence of Time to Reperfusion on Myocardial Salvage. Workshops on the Pathophysiology of Myocardial Ischemia, Infarction, and Remodeling. 30th International Congress on Electrocardiology. Helsinki, Finland. June 11, 2003.
30. ST Elevation Myocardial Infarction. Current Concepts on Early Recognition and Practical Problems. Niagara Falls, Canada. April 2006
31. New modalities for the treatment in Chronic Heart Failure. Moody Garden, Galveston Texas. Schedule for April 2006
32. Time to Treatment in Acute Myocardial Infarction. It is time to Reduce it. The Time Study. Kholn Germany July 2006
33. Optimizing treatment in Heart Failure to prevent Readmission. November 2006. Family Medicine UTMB
34. UTMB Providers Network Breakfast Conference. Heart Failure Epidemic. How to prevent Hospital Admission. February 27, 2007, UTMB Administration Building
35. Heart Failure 2007. Fellowship program UTMB. January 2007
36. ACC 2007 highlights. Houston Heart Failure Society. Houston, Texas. June 7, 2007
37. Heart Failure Up to Date. Combined Cardiology Fellowship program UTMB-Houston Methodist Hospital July 2007
38. Participant of the Journal of Electrocardiology ECG/Defibrillator Working Group 2007: Guidelines for Facilitating the Availability of Devices Required for Recording and Transmitting Prehospital 12-lead ECGs.
39. Chairperson in Telemedicine and Community Health. 34th Annual Computers in Cardiology meeting in Durham from Oct 2nd 2007
40. Invited Speaker American Heart Association. Scientific Sessions 2007 ECG in ACS: From Initial Symptoms through Hospitalization. ECG Decision-Making in the Emergency Department. Session number DS 22. Room W224 of November 05, 2 to 5 PM
41. Invited Speaker. Newer approaches in the management of Heart failure. Primer Alumni y Becarios del Sanatorio Guemes. November 30 Buenos aires Argentina.2007
42. Invited Speaker Session title: Growing practice of non-pharmacological treatment in congestive heart failure” Integration of Remote Monitoring into Heart Failure Management” World Congress of Cardiology 2008. Buenos Aires, Argentina. May 21, 2008
43. Chair Session Advances in cardiopulmonary resuscitation 19 May 2008. 10:30-12:00 Location: Tigris, Yellow Pavillion. Session 2826. World Congress of Cardiology 2008. Buenos Aires, Argentina. May 19, 2008

44. Invited Speaker 16th Annual Essential in Internal Medicine: Update on Principles and Practice Congestive Heart Failure 2009. April 3, 2009. Moody Gardens Hotel, Spa and Convention Center.
45. Cardiology University of Texas Medical Branch UTMB-Methodist Fellows Conference: Management of Congestion and Diuretic resistance in Chronic Heart Failure. August 20, 2009
46. TCT in conjunction with Argentinean Society of Angiography and Cardiac Interventions. Buenos Aires, argentina. "Revascularization in Ischemic Cardiomyopathy" Buenos Aires Argentina October 3, 2009.
47. Internal Medicine Grand Round. Schedule for January 7, 2010 "Cardiorenal Syndrome in Heart Failure"
48. Invited Co-Chair Tenth Staff Symposium Belfast Ireland. September 30-Oct 2, 2010.
49. Invited Speaker Argentinean Congress of Cardiology. Argentinean Interventional cardiology Society. "Interventions in Heart Failure: Disease Management and Therapy". Ultrafiltration Devices. October 9, 2010
50. Invited Speaker Heart Failure 2010. State of the Art Management. Heart Failure. Which Arrhythmia to treat? American Heart Association 2010.
51. Invited Speaker Interamerican Society of Cardiology Congress, Cartagena Colombia, March 2011. Invasive Heart Failure. – "Advance Heart Failure Management" "Diuresis, Aquapheresis or aquaresis in advance heart failure management"
52. Invited Speaker Interamerican Society of Cardiology Congress, Cartagena Colombia, March 2011. Invasive Heart Failure. "State of the Art Management of Advance Heart Failure"
53. Chair Session International Congress Electrophysiology. "Role of Autonomic System in Sudden Cardiac Death" 2011 Kingston Canada
54. Invited Speaker and Chair Session "Interventions in Heart Failure" Joint Sessions TCT-CACI to be held in Buenos Aires, Argentina October 1-2; 2011.
55. Invited Speaker "Advance Heart Failure Management" Santiago de Chile October 16-17, 2012.
56. Invited speaker Staff International Meeting, Poland, Krakow 2012. Prehospital care in AMI. Role of telemedicine.
57. Invited Speaker Interamerican Society of Cardiology/Argentinean Congress of Cardiology October 2013 Percutaneous and surgical Assist Devices in Advanced Heart Failure. October 2013 Buenos Aires Argentina
58. Invited Speaker SOLACI Congress (Latin American Interventional Cardiology 2014. Percutaneous Assist Devices in Advanced Heart Failure. Buenos Aires Argentina
59. Invited Speaker World Congress of Cardiology 2014, Prehospital care of Acute Myocardial Infarction. Sydney Australia May 2014
60. Invited Speaker National Mexican Congress, ANCAM October 2014, Heart Failure and the obesity paradox
61. Invited Speaker ISCP International Society of cardiovascular pharmacotherapy June 2015, Management of Fluid Overload in Heart Failure. Buenos Aires, Argentina
62. Invited Speaker Primer simposio en insuficiencia cardiaca Clinica Bazterrica-Santa Isabel. June 2015, Assist Devices in Heart Failure. Buenos Aires Argentina
63. Invited Chair Session. Insuficiencia Cardiaca 2015. Sociedad Argentina de Cardiologia octubre 2015. Buenos Aires Argentina
64. Invited Speaker. Cardiorenal syndrome. Paraguayan Society of Internal Medicine, Abril 28, 2016 Asuncion Paraguay
65. Invited Speaker. Ventricular Assist Devices. Current and Future Perspectives. Paraguayan Society of Internal Medicine, Abril 28, 2016 Asuncion Paraguay
66. Invited Chair Session. Insuficiencia Cardiaca . Federacion Argentina de Cardiologia Mayo de 2016. Cordoba Argentina

67. Invited Speaker Segunda Sesión estatutaria. AHA representative. Sociedad Mexicana de Cardiología, Querétaro Mexico. Julio 1-2, 2016.
68. Invited Speaker. Insuficiencia Cardíaca. Sociedad de Cardiología de Salta. Federación Argentina de Cardiología Setiembre de 2016. Salta Argentina
69. Invited Speaker. Insuficiencia Cardíaca 2016. Sociedad Argentina de Cardiología October 2016. Buenos Aires Argentina
70. Invited Speaker. Duke Clinical Research Institute Learning Lab and Novartis LA Heart Failure Program. October 20-21, 2016
71. Speaker. Joint Session. American Heart Association/FAC Invited Speaker Federación Argentina de Cardiología. Rosario junio 1, 2017. Estrategias para reducir el tamaño del infarto y mejorar los resultados. (AHA Mission Lifeline)
72. Speaker. American Heart Association representative, Invited Speaker Federación Argentina de Cardiología. Rosario junio 1, 2017.
73. Conferencia. Sociedad Argentina de Cardiología 2017. Vasodilatadores en Insuficiencia Cardíaca Aguda Descompensada
74. Conferencia. Sociedad Argentina de Cardiología 2017. Insuficiencia cardíaca, diabetes y disfunción renal: Una asociación frecuente y compleja
75. American Heart Association representative, Invited Speaker Federación Argentina de Cardiología. Mendoza junio 1, 2018. Shock Cardiogénico post infarto. Tiempo a la Descompresión
76. American Heart Association representative, Invited Speaker Federación Argentina de Cardiología. Mendoza junio 1, 2018. Nuevos dispositivos para el manejo de la insuficiencia cardíaca
77. American Heart Association representative, Invited Speaker Federación Argentina de Cardiología. Mendoza junio 1, 2018. Insuficiencia Cardíaca y diabetes en la mujer. Amistades peligrosas
78. Conferencia. Sociedad Argentina de Cardiología. Congreso Argentino de Cardiología. Insuficiencia cardíaca. Terapia de destino con dispositivos de asistencia circulatoria. ¿Hay futuro para la terapia de destino en Argentina? Buenos Aires octubre 2018
79. Congress Chair. Tercer simposio del manejo de la insuficiencia cardíaca en la era de los dispositivos artificiales Dr Domingo Liotta. Universidad Católica Argentina. Septiembre 2018
80. American Heart Association Joint Session, Invited Speaker HFE 2018 Conclave. Heart Failure Essentials. Chennai, India September 2018. Biomarkers in heart failure
81. American Heart Association Joint Session, Invited Speaker HFE 2018 Conclave. Heart Failure Essentials. Chennai, India September 2018. Advanced Heart Failure and LVAD
82. American Heart Association Joint Session, Invited Speaker HFE 2018 Conclave. Heart Failure Essentials. Chennai, India September 2018. Inotropic update and new molecules in HF
83. American Heart Association Joint Session, Invited Speaker HFE 2018 Conclave. Heart Failure Essentials. Chennai, India September 2018. Cardiogenic Shock
84. Chair session. American Heart Association representative, Invited Speaker. Spanish Congress of Cardiology. October 2018. Insuficiencia Cardíaca Avanzada. 'New Challenges in Heart Failure' España, Sevilla 2018
85. Speaker. Current State of Assisted Circulation in Advanced Heart Failure held on Thursday, October 25, 2018. Sevilla - FIBES during SEC 2018 - The Congress of Cardiovascular Diseases.
86. Sevilla, October 27, 2018 Manuel Anguita Sánchez, President of the SEC American Heart Association Joint Session
87. Invited Speaker. Italian Congress of Cardiology. Rimini Italy May 2019. Chair Session. Cardiac disease in women
88. Speaker. Joint Session AHA-FAC Mayo 31, 2019. Enfermedad Cardiovascular en la Mujer. Go Red For Women. Rosario, Argentina

89. Results of the DUCCS STLEUIS study using a smartphone for triage and monitoring in STEMI patients. STAFF Symposium Les Diablerets, Switzerland, 04-07 September 2019
90. Chair Session. Joint Symposium American Heart Association/AMNCO. Italian Lancisi Symposium. Conero Riviera, Ancona. Go Red for women Powered by Artificial Intelligence. '20 years of the *"Lancisi Heart Days"*. November 23, 2019.
91. Disertante, Invitado Internacional. Primera Jornada Internacional de Cardiología. Clínica El Castaño. Debates actuales en Insuficiencia Cardíaca. 01 de noviembre de 2019. San Juan capital
92. American Heart Association Joint Session, Chair Session Italian Lancisi Symposium. Conero Riviera, Ancona. November 2019. Go Red for women License Signature
93. Congress Director. IV International Summit 2019. Heart Failure and Pulmonary Hypertension. Virtual Congress December 2019
94. V Heart Failure Review 2020. Liotta Symposium. Co-chair of the Virtual Conference. Buenos Aires Argentina.
95. Speaker "Diabetes e Insuficiencia Cardíaca" Cardioacademics, Octubre 2020
96. Speaker, Cardiometabolismo e insuficiencia cardíaca: papel de la diabetes mellitus. Congreso del Colegio de Medicina Interna de México (CMIM). Modalidad Virtual. Mexico Diciembre 2020
97. Speaker, Cardiometabolismo e insuficiencia cardíaca: hipertensión y obesidad en la insuficiencia cardíaca. Congreso del Colegio de Medicina Interna de México (CMIM). Modalidad Virtual. Mexico Diciembre 2020
98. Speaker. ANCAM Asociacion Nacional de Cardiólogos de Mexico. Primera reunión virtual. Heart Failure Epidemics. Novel Approaches. Abril 16, 2021
99. AMNCO Conference Speaker at the Italian Cardiology Meeting 2021
100. AHA Women Heart at Cardioacademics Symposium, Mexico 2021
101. Speaker. Joint Symposium American Heart Association/Argentinean Society of Cardiology. Emerging Therapies in Heart Failure. Congreso Argentino de Cardiología. Buenos Aires, Argentina 2021
102. Congress Director. VI International Summit 2021. Heart Failure and Pulmonary Hypertension. Virtual Congress December 2021
103. Primera Sesión Estatutaria de la Sociedad Mexicana de Cardiología 11 y 12 de marzo del 2022. Chair Session. Sociedad Mexicana de Cardiología. Mexico DF. Mexico. Hotel Camino Real. Marzo 2022
104. Speaker. Trombo 360 Edición 2022. 'Insuficiencia Cardíaca como enfermedad protrombótica' 6 de mayo 2022. Merida Mexico. Hotel Hyatt.
105. Speaker. 52 congreso italiano de cardiología 19-22 de mayo 2022. Associazione Nazionale Medici Cardiologi Ospedalieri ANMCO-POWER. Rimini. Italy. Opening Ceremony.
106. Speaker. 'Treatment of Advanced Heart Failure: Mechanical vs. Biological' Sociedad Interamericana de Cardiología. Miami, USA Junio 2022
107. Speaker. Segundo Simposio Argentina Bolivia. Virtual. Dispositivos en Insuficiencia Cardíaca. Septiembre 2022
108. Speaker. Tercera Sesión Estatutaria de la Sociedad Mexicana de Cardiología. Cardiopatía y género. Sesión Conjunta AHA-SMC "Gender Difference in Heart Failure" Tijuana, Merida. Nov 2022.
109. Speaker. Primer Simposio de Insuficiencia Cardíaca. 'Síndrome cardiorenal en el desarrollo de la Insuficiencia Cardíaca' Cuenca Ecuador. 10-12 noviembre 2022
110. Speaker. Primer Simposio de Insuficiencia Cardíaca. 'manejo de la anticoagulación y antiagregación en la Insuficiencia Cardíaca' Cuenca Ecuador. 10-12 noviembre 2022
111. Speaker. Sesión Conjunta FAC - SEC -AHA Fibrilación auricular. Lo que el clínico debe saber Tema: Fibrilación auricular e insuficiencia cardíaca. ¿Qué hay de nuevo? 1-3 junio 2023 Federación Argentina de Cardiología.
112. Presidente de la Sesión Conjunta FAC - SEC -AHA Fibrilación auricular. Lo que el clínico debe saber. 1-3 junio 2023 Federación Argentina de Cardiología.

- 113.Coordinador: Los distintos panoramas y novedades en Insuficiencia cardíaca, ¿Cuándo, ¿cómo y a quién?
Organizado por ISHLT español y Grupo ILAPH 29 junio, 2023
- 114.Speaker Incontro con Lésperto- La Ricerca Clinica un Ponte Sull Óceano: Quali Sviluppi Per La Fondazione Per Il Tuo Cuore. 18th May 2023 "Tavola rotonda sul tema della ricerca clinica" 54 Congresso Nazionale Medici Cardiologi Ospedalleri. May 18, 2023
- 115.Speaker. Tendencias Actuales en el Manejo del Shock Cardiogenico. Congreso Virtual, Junio 2023 Bolivia Santa Cruz de la Sierra.
- 116.Speaker. Simposio Salud e Innovacion. Digital Medicine in Cardiology/Heart Failure. Lima, Peru. 2 de Mayo 2023
- 117."Evidencias en insuficiencia cardíaca. ¿Cómo reducir el fracaso terapéutico? Sesión Conjunta SAC-FAC" Octubre 2023
- 118.Speaker. Congreso Mexicano de Cardiología. Insuficiencia Cardíaca con FEV preservada. Acapulco Mexico 2024
- 119.Speaker. Insuficiencia Cardíaca avanzada. Congreso Federación de cardiología Argentina FAC. Rosario, Argentina mayo 2024
120. Speaker. Insuficiencia cardíaca con FEV preservada. Congreso Federación de cardiología Argentina FAC. Rosario, Argentina Mayo 2024
- 121.III Curso de FALLA CARDÍACA e IMÁGENES CARDIOVASCULARES SISIAC-Siegfried, Coordinador. Mayo 2024. Streaming
- 122.Conferencia. III CURSO DE IMÁGENES CARDIOVASCULARES Y FALLA CARDÍACA SISIAC-SIEGFRIED. SISIAC agosto,2024
- 123.Dispositivos de asistencia circulatoria" módulo "Insuficiencia cardíaca con fracción de eyección disminuida" del Curso Internacional de Insuficiencia Cardíaca, Academia Nacional de Medicina de Buenos Aires en modalidad virtual. Octubre 2024
- 124.Invitado especial. Registro Cruceño de Insuficiencia Cardíaca. Sociedad Cruceña de Cardiología. Santa Cruz de la Sierra, Bolivia, agosto 2024
- 125.Valoración de la congestión pulmonar por impedancia eléctrica del tórax: estado actual y perspectivas futuras. SAC October 2024
- 126.Miopatía auricular, empoderando la cavidad olvidada sobre el tema Insuficiencia cardíaca: cuando el culpable no es el ventrículo. SAC October 2024
- 127.CIAT Summit Internacional. Insuficiencia cardíaca con FEV reducida: más allá de los 4 fantásticos. Tucumán 2024
- 128.Speaker. Joint sesión AHA-FAC Obesidad e Insuficiencia cardíaca. Congreso Federación de cardiología Argentina FAC. Mendoza, Argentina Mayo 2024
- 129.SIMPOSIO CONGIUNTO AHA-AMNCO INNOVATION AND AI IN CARDIOLOGY: FROM PREVENTION TO PERSONALIZED THERAPY. Roundtable discussion. Rimini, May 2025

ACADEMIC TITLES AND MEMBERSHIPS

- Adjunct Professor Duke University School of Medicine (2015-current)
- Associate Professor of medicine. University of Texas Medical Branch (2005-2013)
- Fellow of the American Heart Association FAHA
- AHA Member of the International Speaker Bureau since 2015
- Fellow of the Society of Cardiac Angiography and Interventions FSCAI
- Past Member Heart Failure Society of America (HFSA)
- Fellow del Colegio internacional de Angiología FICA

- Member American Heart Association.
- Titular member of the Argentinean Society of Cardiology (MTSAC)
- 2022-Present Member of the Scientific Honorary Board ‘Fondazione per Il Tuo Cuore-Heart Care Foundation

COMMITTEES

- IRB Review Board Committee 2005 to 2010. University of Texas Medical Branch
- Therapeutic Hypothermia Committee. University of Texas Medical Branch.2005
- Participant of the Journal of Electrocardiology ECG/Defibrillator Working Group 2007: Guidelines for Facilitating the Availability of Devices Required for Recording and Transmitting Prehospital 12-lead ECGs
- Duke University Clinical Cardiovascular Society (DUCCS) Board Committee Member 2011-present
- Houston Heart Failure Society Committee. From 2006 to 2013
- Participate as Director of the Auction Committee in the 2012 American Heart Gala in Galveston
- SCAI Interventional Heart Failure Committee Member
- AHA Clinical Cardiology Council Committee Member
- ST Louis Clinical Trial Steering Committee

LICENSURE INFORMATION

- Jan 1, 2005- 2013 Texas State Board of Medical Examiners License yearly renewal.
2013 License Number 44164 (FTP Faculty temporary license)
- Dec 30, 1982 National License issued by the National Public Health Organization in Argentina
- LN 64737
- Jan 22, 1998 Buenos Aires State License. LN 446172
- Feb 20, 1991 Board certified In Cardiology, Issued by the National Public Health Organization.
- Apr 16, 1998 Board recertification in Cardiology. Issued by Argentine Society of Cardiology and Argentine Medical Association
- DPS J0165133
- DEA number FB1811288
- TPI (Title program identification Number): 170580801
- BCBS provider number 8M8569
- Blue Link ID 4324561
- Aetna # 07463644
- NPI [1972662773](#)

RESEARCH GRANTS

- Argentinean Society of Cardiology. International Scholar. Dept Artificial Organs. Cleveland Clinic Foundation. (Oct-Dec 1990).

- Favaloro Foundation. Development of the cardiovascular databank with Duke University Medical Center. Project Leader. 1992-1994
- Medco Research Inc. Safety and efficacy of adenosine in the treatment of acute myocardial infarction. Steering Committee member (1995-1996)
- Otsuka Maryland Research Institute. Tolvaptan research program in congestive heart failure. (ACTIV in CHF). Steering Committee Member (2002-2004)
- Principal Investigator. Tolvaptan-Amiodarone Interaction. A phase I trial. (2004)
- Site Principal Investigator. AMISTAD Trial. Acute Myocardial Infarction Study Adenosine. (1995-1996)
- Site Principal Investigator. Paragon B Study. Integrelin in Non-ST elevation Myocardial Infarction. 1997
- Principal Investigator. Everest trial in Congestive Heart Failure. 2006
- Principal Investigator. Acclaim Study in Congestive Heart Failure. 2006
- Principal Investigator RED-HF Trial in Congestive heart Failure 2007
- Study Co- PI. TIME Multicenter Study in Acute Myocardial Infarction.
- Educational grant, Half position for Heart Failure Fellowship 2008-2009. Grants provided by Boston Scientific. 25 K
- Educational grant, Full position for Heart Failure Fellowship 2009-2010. Grants provided by Houston Methodist Hospital. 60 K
- NIH Heart Failure Network. Implementation Phase along with the Internal Medicine NIH Research. CARESS Trial. Ultrafiltration in Heart Failure
- Research Grant Claude Pepper Older American Independence Center 2009-2010

(SEALY CENTER ON AGING): “Skeletal muscle microvascular perfusion and the obesity paradox in CHF” **FRS: 425988/ Project: 80863/Bud Ref: 04** 100 K

- Research Grant Claude Pepper Older American Independence Center 2009-2010

(SEALY CENTER ON AGING): “Downhill Walking and mitigation of Muscle Decline over Aging” 50K, Co-Investigator

- Otsuka Registry. An Observational Prospective Registry to Identify Demographic and Clinical Characteristics of Patients Hospitalized with Euvolemic and Hypervolemic Hyponatremia and Assess the Comparative Effectiveness of Available Treatments
- Mentor of NIH grant support to the PhD Kyle Timmenmann. Role of peripheral inflammatory activation in muscle dysfunction and cachexia in Chronic Heart failure. The role of TLR4 receptor. Grant Submitted
- Steering Committee member ST Louis Clinical Trial. Grant AliveCore
- Steering Committee member REPLACE Covid Randomized Trial. UPenn
-

PATENTS

1. US Patent US 9,308,379 B2 Cardiac Treatment Apparatus 2016
2. US Patent US 9,750,948 B2 Cardiac Treatment Apparatus 2017

HONORS AWARDS

- Honor with a recognition for his medical career in the First Alumni in Buenos Aires Argentina November 30, 2007. Sanatorio Guemes.
- Included in the Archives of Duke University for being instrumental in the development of the first international research databank for Cardiovascular Diseases
- Honorary Member of the SPCIC Sociedad Paraguaya de Cuidados Intensivos Cardiovasculares
- Hall of Fame. SaludX. www.saludx.pe Lima 27 marzo 2025

BOOK CONTRIBUTIONS

- “Atlas of Advanced ECG Interpretation”. Pulino Alvarez, MD, Alejandro Barbagelata, MD. Hypercalcemia . REMEDICA 2009 Editor Adrian Baranchuk, MD, FACC.
- Prehospital Management of ACUTE STEMI. An International Perspective. Prof. Edgardo Escobar, Alejandro Barbagelata. 2015. Joseph Alpert Editions. Cardiotext